[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 412
1. Zada G, McNatt SA, Gonzalez-Gomez I, McComb JG: Anaplastic intraventricular oligodendroglioma: case report and review of the literature. Surg Neurol; 2009 Jun;71(6):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic intraventricular oligodendroglioma: case report and review of the literature.
  • BACKGROUND: Intraventricular oligodendroglioma remains a rare diagnosis, with high-grade/anaplastic IVO being an even rarer subtype.
  • These lesions vary in regard to tumor grading and clinical presentation, as compared with their intraparenchymal counterparts.
  • A case report and review of the previous literature regarding IVO and tumor grading were conducted.
  • CASE DESCRIPTION: A case report of a patient with an anaplastic oligodendroglioma confined entirely within the ventricular system is presented.
  • Only 2 previous case reports of high-grade/anaplastic IVO were identified.
  • Adjuvant therapies may differ significantly according to the tumor grade and molecular subtype.
  • CONCLUSIONS: Intraventricular oligodendroglioma remains an infrequently encountered lesion, yet is usually found to be low grade at the time of surgery.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery
  • [MeSH-minor] Female. Humans. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291495.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


2. Yamamoto M, Iwaasa M, Nonaka M, Tsugu H, Nabeshima K, Fukushima T: Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma. Anticancer Res; 2005 Nov-Dec;25(6A):3715-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
  • The safety, tolerance and preliminary efficacy of a chemotherapy regimen consisting of procarbazine (PCB), ranimustine (MCNU) and vincristine (VCR) were assessed for patients with newly diagnosed supratentorial anaplastic oligodendroglioma.
  • The cycles were repeated every 8 weeks until tumor progression was evident, or for a total of 6 cycles over a 1-year period.
  • However, 3 of the 5 patients showed relapse, with a time to tumor progression (TTP) of 50, 143 and 241 weeks, respectively.
  • Two of these patients received combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha at the first relapse.
  • This regimen appeared to be safe and neither neurological toxicity, severe or life-threatening hematological toxicity, nor fatal toxicity (WHO Grade 4) were experienced.
  • However, since the relapse rate was high, a second-line chemotherapy should be developed for anaplastic oligodendroglioma to improve the long-term control of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


3. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol; 2008 Jul;88(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.
  • PURPOSE: To assess the frequency of chromosomes 1p and 19q deletions in gliomas and to correlate 1p deletion with prognosis in patients with grade 2 and grade 3 gliomas independently of histologic subtype.
  • METHODS: We retrospectively evaluated 208 patients with WHO grade 2 and 3 gliomas who had 1p/19q molecular studies performed between 2000 and 2004.
  • DNA was extracted from tumor tissue and germline material and evaluated by PCR using microsatellite markers for each chromosome.
  • Thirty-eight patients had a low-grade astrocytoma (A2), 58 low-grade oligodendroglioma (O2), 31 low-grade oligoastrocytoma (OA2), 21 anaplastic astrocytoma (A3), 37 anaplastic oligodendroglioma (O3), and 23 had an anaplastic oligoastrocytoma (OA3).
  • On multivariate analyses, chromosome 1p was a prognostic factor for prolonged PFS (HR = 1.75, P = 0.03) and OS (HR = 3.59, P = 0.02) in grade 2 gliomas but not for grade 3 (HR = 0.81, P = 0.7 for PFS; HR = 1.31, P = 0.7 for OS).
  • CONCLUSION: Chromosome 1p deletion is a significant positive prognostic marker in diffuse, grade 2 gliomas regardless of histologic subtype.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Glioma / genetics
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Gene Deletion. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats / genetics. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):828-37 [16819324.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4758-63 [16966689.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):855-65 [15929038.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):348-56 [1283324.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):322-6 [16049942.001]
  • (PMID = 18345516.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Seifert M, Ampofo C, Mehraein Y, Reichrath J, Welter C: Expression analysis of human intersectin 2 gene (ITSN2) minor splice variants showing differential expression in normal human brain. Oncol Rep; 2007 May;17(5):1207-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of human intersectin 2 gene (ITSN2) minor splice variants showing differential expression in normal human brain.
  • Using RT-PCR-studies we analyzed ITSN2 minor splice variants and their expression in an adult tissue panel.
  • Differential expression was demonstrated for a previously described minor splice variant including exon 16 (ITSN2C) with a relative increase in adult human brain tissue.
  • Additional comparative expression analyses in oligodendrogliomas furthermore revealed differential expression with lack of this specific minor splice variant in the brain tumor tissue.
  • [MeSH-major] Adaptor Proteins, Vesicular Transport / biosynthesis. Brain / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390067.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Vesicular Transport; 0 / ITSN2 protein, human; 0 / Protein Isoforms
  •  go-up   go-down


5. Shah MN, Leonard JR, Perry A: Rosette-forming glioneuronal tumors of the posterior fossa. J Neurosurg Pediatr; 2010 Jan;5(1):98-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare, recently described WHO Grade I neoplasm.
  • The original diagnoses included pilocytic astrocytoma, ependymoma, cerebellar dysembryoplastic neuroepithelial tumor (DNT), and oligodendroglioma.
  • These cases expand the known clinical and histological spectrum of this rare tumor type.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Cranial Fossa, Posterior. Ependymoma / diagnosis. Ependymoma / surgery. Magnetic Resonance Imaging. Neuroectodermal Tumors, Primitive / diagnosis. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043744.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O'Neill BP, Giannini C, Brown PD: Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol; 2009 Aug;11(4):437-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic.
  • The purpose of this study was to evaluate long-term survival in patients with nonpilocytic low-grade gliomas (LGGs).
  • Records of 314 adult patients with nonpilocytic LGGs diagnosed between 1960 and 1992 at the Mayo Clinic, Rochester, Minnesota, were retrospectively reviewed.
  • Operative pathology revealed pure astrocytoma in 181 patients (58%), oligoastrocytoma in 99 (31%), and oligodendroglioma in 34 (11%).
  • Adverse prognostic factors for OS identified by multivariate analysis were tumor size 5 cm or larger, pure astrocytoma histology, Kernohan grade 2, undergoing less than rSTR, and presentation with sensory motor symptoms.
  • Statistically significant adverse prognostic factors for PFS by multivariate analysis were only tumor size 5 cm or larger and undergoing less than rSTR.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1338-45 [18323558.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24 [21549518.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25 [15093907.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Cancer. 1975 Nov;36(5):1681-9 [172217.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Br J Clin Pharmacol. 1982 Sep;14(3):325-31 [6751362.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):975-82 [3614580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41 [3141317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8 [2921165.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Neurosurgery. 1989 May;24(5):686-92 [2716976.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):554-9 [8474646.001]
  • [Cites] W V Med J. 1993 Mar;89(3):102-5 [8475621.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Acta Neurochir (Wien). 1993;123(1-2):1-7 [8213272.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):173-7 [8699240.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 1999 Mar 10;52(4):867-9 [10078745.001]
  • (PMID = 19018039.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P30 CA15083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2743224
  •  go-up   go-down


7. Stadlbauer A, Nimsky C, Gruber S, Moser E, Hammen T, Engelhorn T, Buchfelder M, Ganslandt O: Changes in fiber integrity, diffusivity, and metabolism of the pyramidal tract adjacent to gliomas: a quantitative diffusion tensor fiber tracking and MR spectroscopic imaging study. AJNR Am J Neuroradiol; 2007 Mar;28(3):462-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The underlying changes in the neuronal connectivity adjacent to brain tumors cannot always be depicted by conventional MR imaging.
  • MATERIALS AND METHODS: Quantitative DT fiber tracking and proton MRSI were performed in 20 patients with gliomas with WHO grades II-IV.
  • The additional use of proton MRSI may be helpful to discern whether these diffusivity changes in fiber tracts are caused by tumor infiltration or peritumoral edema.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Oligodendroglioma / pathology. Pyramidal Tracts / pathology
  • [MeSH-minor] Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Astrocytoma / metabolism. Astrocytoma / pathology. Creatine / metabolism. Female. Humans. Hypesthesia / metabolism. Hypesthesia / pathology. Image Processing, Computer-Assisted. Male. Middle Aged. Nerve Fibers / metabolism. Nerve Fibers / pathology. Paresis / metabolism. Paresis / pathology. Paresthesia / metabolism. Paresthesia / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353313.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine
  •  go-up   go-down


8. Ogawa K, Yoshii Y, Toita T, Saito A, Kakinohana Y, Iraha S, Sugimoto K, Tsuchida Y, Tamaki W, Adachi G, Hyodo A, Murayama S: Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study. Anticancer Res; 2006 May-Jun;26(3B):2457-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiotherapy and multi-agent chemotherapy (procarbazine, ACNU and vincristine) for high-grade gliomas: a prospective study.
  • AIM: To evaluate the feasibility, efficacy and toxicity of hyperfractionated radiotherapy and multi-agent chemotherapy, including procarbazine, nimustine (ACNU) and vincristine, in adults with high-grade gliomas.
  • RESULTS: From September 1997 to August 1999, a total of ten patients (five with glioblastoma and five with grade 3 gliomas) were enrolled.
  • Although grade 4 leukopenia and grade 4 thrombocytopenia occurred in 10% and 10% of all patients, respectively, these were transient and no patients developed neutropenic fever or intracranial hemorrhage.
  • CONCLUSION: Hyperfractionated radiotherapy and multi-agent chemotherapy using procarbazine, ACNU and vincristine is safe and well tolerated for high-grade gliomas.
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Nimustine / administration & dosage. Nimustine / adverse effects. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy. Procarbazine / administration & dosage. Procarbazine / adverse effects. Prospective Studies. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / radiotherapy. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821632.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0S726V972K / Nimustine; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine
  •  go-up   go-down


9. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol; 2007 Apr;14(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
  • Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.
  • Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies.
  • We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery.
  • All the tumors were low grade (grade II) pure OG according to the WHO classification.
  • Response was evaluated by clinical assessment and brain magnetic resonance imaging.
  • Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Disease-Free Survival. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388986.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


10. Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C: Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India; 2009 Sep-Oct;57(5):559-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
  • RESULTS: Glial fibrillary acidic protein immunopositivity was observed in oligodendrogliomas within minigemistocytes and gliofibrillary oligodendrocytes as perinuclear homogenous blobs.
  • 1p and/or 19q loss was seen in 65% (13/20) of oligodendrogliomas and 66.6% (5/9) of mixed oligoastrocytomas.
  • There was one case each of pediatric oligodendroglioma and mixed oligoastrocytoma, none of which showed 1p/19q loss.
  • p53 was expressed in 57.1% of astrocytomas (8/14), 33% of mixed oligoastrocytomas (3/9) and 10% of oligodendrogliomas (2/20).
  • Majority of oligodendrogliomas (85%; 17/20) and oligodendroglial areas in mixed oligoastrocytomas (77.7%; 7/9) showed a membranous lace-like immunopositivity with EGFR.
  • In contrast, all astrocytomas (Grade II and III) were EGFR negative.
  • CONCLUSION: Loss of 1p/19q is strongly associated with oligodendroglial phenotype, while astrocytic tumors are more likely to show p53 over-expression. p53 expression and 1p/19q status appear to be mutually exclusive.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 19. In Situ Hybridization, Fluorescence / methods. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934553.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


11. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, Saltz JH, Brat DJ, Moreno CS: The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One; 2010 Sep 03;5(9):e12548
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
  • Despite the richness of TCGA GBM data, the absence of lower grade gliomas in this data set prevents analysis genes related to progression and the uncovering of predictive signatures.
  • A complementary dataset exists in the form of the NCI Repository for Molecular Brain Neoplasia Data (Rembrandt), which contains molecular and clinical data for diffuse gliomas across the full spectrum of histologic class and grade.
  • We demonstrate that the proneural signature predicts improved clinical outcome among 176 Rembrandt gliomas that includes all histologies and grades, including GBMs (log rank test p = 1.16e-6), but also among 75 grade II and grade III samples (p  =  2.65e-4).
  • This gene expression signature was enriched in tumors with oligodendroglioma histology and also predicted improved survival in this tumor type (n =  43, p  =  1.25e-4).
  • Thus, expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for lower grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.
  • Integrated DNA and RNA analysis of low-grade and high-grade proneural gliomas identified increased expression and gene amplification of several genes including GLIS3, TGFB2, TNC, AURKA, and VEGFA in proneural GBMs, with corresponding loss of DLL3 and HEY2.
  • This demonstrates that the expression signatures identified in the TCGA analysis of GBMs also have intrinsic prognostic value for low-grade oligodendrogliomas, and likely represent important differences in tumor biology with implications for treatment and therapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 9;354(2):567-73 [17250806.001]
  • [Cites] Bioinformatics. 2007 Dec 1;23(23):3251-3 [17644558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] BMC Genomics. 2007;8:461 [18088408.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Mol Cancer Res. 2009 Feb;7(2):157-67 [19208739.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2091-9 [19244127.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):98-110 [20129251.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):510-22 [20399149.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):837-49 [10879735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] EMBO J. 1988 Oct;7(10):2977-82 [2460335.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L173-80 [7532367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Mar;87:473-9 [13919885.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Bioinformatics. 2006 Jan 1;22(1):122-3 [16269418.001]
  • [Cites] Blood. 2006 Feb 1;107(3):931-9 [16219802.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • (PMID = 20838435.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / PHS HHS / / S09-094; United States / NIBIB NIH HHS / EB / P20 EB000591; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / NCRR NIH HHS / RR / UL1 RR025008; United States / NLM NIH HHS / LM / R01 LM011119
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2933229
  •  go-up   go-down


12. Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z: Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol; 2009 Apr;30(4):681-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Current classification and grading of primary brain tumors has significant limitations.
  • MATERIALS AND METHODS: Thirty-four patients with gliomas (WHO grade I-IV, 27 astrocytomas, 7 tumors with oligodendroglial components) underwent contrast-enhanced MR rCBV measurements before treatment.
  • Receiver operating characteristic curves and Kaplan-Meier survival analysis were conducted for CBV and histologic grade (WHO grade).
  • RESULTS: Significant correlations were detected only when patients with oligodendrogliomas and oligoastrocytomas were excluded.
  • WHO grade correlated with rCBV values (r = 0.65, P < or = .0002).
  • The relative risk for shorter PFS was 11.1 times higher for rCBV(max) > 4.2 (P = .0006) and 6.7 times higher for WHO grade > II (P = .05).
  • The combined CBV-WHO grade classification enhanced the predictive value for recurrence/progression (P < .0001).
  • CONCLUSIONS: rCBV values in astrocytomas but not tumors with oligodendroglial components are predictive for recurrence and 1-year survival and may be more accurate than histopathologic grading.
  • [MeSH-major] Astrocytoma / pathology. Blood Volume. Brain Neoplasms / pathology. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis. ROC Curve. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179427.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Houben MP, Coebergh JW, Birch JM, Tijssen CC, van Duijn CM, McNally RJ: Space-time clustering of glioma cannot be attributed to specific histological subgroups. Eur J Epidemiol; 2006;21(3):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously showed that infectious exposures may be involved in the aetiology of adult glioma, by analysing for space-time clustering using population-based data from the South of the Netherlands.
  • There was only statistically significant space-time clustering for oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / epidemiology. Geography. Glioma / epidemiology. Space-Time Clustering
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Astrocytoma / classification. Astrocytoma / epidemiology. Ependymoma / epidemiology. Female. Geographic Information Systems. Humans. Male. Middle Aged. Netherlands / epidemiology. Oligodendroglioma / epidemiology. Registries. Risk Factors. Sex Distribution

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):929-38 [15870157.001]
  • [Cites] Adv Virus Res. 1998;50:69-99 [9520997.001]
  • [Cites] Virology. 2004 Jan 5;318(1):1-9 [15015494.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):460-3 [12750243.001]
  • [Cites] Radiat Res. 1998 Sep;150(3):357-64 [9728664.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1070-7 [11953851.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2917-23 [16274986.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Neuropathology. 2005 Mar;25(1):1-7 [15822813.001]
  • [Cites] Int J Epidemiol. 1993 Jun;22(3):412-9 [8359956.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):746-50 [12232758.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):173-82 [12707848.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1844-51 [10468308.001]
  • [Cites] Cancer Causes Control. 1996 Jul;7(4):437-48 [8813432.001]
  • [Cites] Am J Public Health Nations Health. 1967 May;57(5):848-56 [6067209.001]
  • [Cites] Cancer Causes Control. 2001 Jun;12 (5):443-9 [11545459.001]
  • [Cites] Neuroepidemiology. 1998;17(5):247-57 [9705584.001]
  • [Cites] Eur J Epidemiol. 1998 Jul;14(5):471-5 [9744679.001]
  • [Cites] Stat Methods Med Res. 1995 Jun;4(2):124-36 [7582201.001]
  • (PMID = 16547834.001).
  • [ISSN] 0393-2990
  • [Journal-full-title] European journal of epidemiology
  • [ISO-abbreviation] Eur. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Leighton C, Fisher B, Macdonald D, Stitt L, Bauman G, Cairncross J: The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J Neurooncol; 2007 Apr;82(2):165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection.
  • PURPOSE: To evaluate the hypothesis that adults with partially resected (PR<50% resection) supratentorial low-grade glioma (LGG) benefit from higher doses of radiation.
  • METHODS: Patients receiving post-operative radiation for WHO grade I-II LGG at the University of Western Ontario between 1979 and 2001 were studied.
  • CONCLUSIONS: The outcome for patients with LGG is dependent on extent of tumor resection and radiation dose.
  • Future trials on therapeutic strategies for LGG should consider stratification of patients by extent of tumor resection.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2007 Dec;85(3):357
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):996-1001 [11958894.001]
  • [Cites] Eur J Cancer. 1998 Nov;34(12):1902-9 [10023313.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):112-6 [8356220.001]
  • [Cites] Jpn J Clin Oncol. 2001 Jun;31(6):240-5 [11463800.001]
  • [Cites] Neurosurgery. 1989 May;24(5):686-92 [2716976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):173-7 [8699240.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • (PMID = 17357830.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • The 6 remaining cases showed features seen in between glioneuronal hamartoma and mixed neuronal-glial tumor.
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • The similar morphologic pattern and biological behavior of glioneuronal hamartoma and mixed neuronal-glial tumor may suggest a common pathogenetic mechanism.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


16. Shaw EJ, Haylock B, Husband D, du Plessis D, Sibson DR, Warnke PC, Walker C: Gene expression in oligodendroglial tumors. Anal Cell Pathol (Amst); 2010;33(2):81-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in oligodendroglial tumors.
  • BACKGROUND: Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity.
  • METHODS: Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy (26 serial stereotactic biopsy, 2 resection).
  • RESULTS: Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status.
  • IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss.
  • Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Cluster Analysis. Drug Resistance, Neoplasm / genetics. Female. Gene Expression. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Principal Component Analysis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966545.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4605574
  •  go-up   go-down


17. Pinto GR, Clara CA, Santos MJ, Almeida JR, Burbano RR, Rey JA, Casartelli C: Mutation analysis of gene PAX6 in human gliomas. Genet Mol Res; 2007;6(4):1019-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common tumors of the central nervous system.
  • Gene PAX6, which encodes a transcription factor that plays an important role in the development of the central nervous system, was recently recognized as a tumor suppressor in gliomas.
  • The objective of the present study was to analyze the mutational status of the coding and regulating regions of PAX6 in 94 gliomas: 81 astrocytomas (11 grade I, 23 grade II, 8 grade III, and 39 grade IV glioblastomas), 5 oligodendrogliomas (3 grade II, and 2 grade III), and 8 ependymomas (5 grade II, and 3 grade III).
  • Therefore, we conclude that the tumor suppressor role of PAX6, reported in previous studies on gliomas, is not due to mutation in its coding and regulating regions, suggesting the involvement of epigenetic mechanisms in the silencing of PAX6 in these tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Eye Proteins / genetics. Glioma / genetics. Homeodomain Proteins / genetics. Mutation. Paired Box Transcription Factors / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Base Sequence. Child. Child, Preschool. DNA Mutational Analysis. DNA Primers / genetics. DNA, Neoplasm / genetics. Ependymoma / genetics. Epigenesis, Genetic. Female. Gene Silencing. Humans. Infant. Male. Middle Aged. Oligodendroglioma / genetics. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273794.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins
  •  go-up   go-down


18. Veilleux N, Goffaux P, Boudrias M, Mathieu D, Daigle K, Fortin D: Quality of life in neurooncology--age matters. J Neurosurg; 2010 Aug;113(2):325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unfortunately, an adult life-stage perspective has never been used to study the long-lasting impact of age on well-being in neurooncology patients.
  • METHODS: In this study, the authors assessed and compared the QOL and QOH scores of 42 younger adults (< or = 40 years of age) and 88 older adults (> 40 years of age) presenting with a primary supratentorial tumor.
  • Moreover, the presence of a high-grade tumor and increased physical pain had a negative impact on the QOH of younger adults, whereas increased difficulty with concentration negatively impacted the QOH of older adults.
  • [MeSH-minor] Adult. Astrocytoma / psychology. Astrocytoma / surgery. Astrocytoma / therapy. Female. Ganglioglioma / psychology. Ganglioglioma / surgery. Ganglioglioma / therapy. Humans. Male. Meningeal Neoplasms / psychology. Meningeal Neoplasms / surgery. Meningeal Neoplasms / therapy. Meningioma / psychology. Meningioma / surgery. Meningioma / therapy. Middle Aged. Oligodendroglioma / psychology. Oligodendroglioma / surgery. Oligodendroglioma / therapy. Predictive Value of Tests. Seveso Accidental Release. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20302393.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol; 2009 Aug;11(4):341-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
  • Codon 132 mutation was seen in 54% of astrocytomas and 65% of oligodendroglial tumors but in only 6% of glioblastomas (3% of primary and 50% of secondary glioblastomas).
  • There were no mutations in any other type of tumor studied.
  • While mutations in the tumor protein p53 gene (TP53) and total 1p/19q deletions were mutually exclusive, IDH1 mutations were strongly correlated with these genetic abnormalities.
  • The data indicate that IDH1 mutation combined with either TP53 mutation or total 1p/19q loss is a frequent and early change in the majority of oligodendroglial tumors, diffuse astrocytomas, anaplastic astrocytomas, and secondary glioblastomas but not in primary glioblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Comparative Genomic Hybridization. Exons / genetics. Genotype. Humans. Loss of Heterozygosity. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):373-84 [10939591.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Feb;34(2):148-57 [11809417.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Free Radic Res. 2003 Mar;37(3):309-16 [12688426.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):362-74 [17534392.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • (PMID = 19435942.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2743214; NLM/ UKMS28703
  •  go-up   go-down


20. Bussière M, Hopman W, Day A, Pombo AP, Neves T, Espinosa F: Indicators of functional status for primary malignant brain tumour patients. Can J Neurol Sci; 2005 Feb;32(1):50-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indicators of functional status for primary malignant brain tumour patients.
  • One hundred and seven patients had a histopathological diagnosis of glioblastoma multiforme, 23 of anaplastic astrocytoma and 13 of anaplastic oligodendroglioma.
  • The anaplastic oligodendroglioma group had lower mortality and maintained better KPS scores over time, as did patients receiving full treatment.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Karnofsky Performance Status
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Radiotherapy. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825546.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Hänninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, Parkkila S: Expression of iron-related genes in human brain and brain tumors. BMC Neurosci; 2009;10:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of iron-related genes in human brain and brain tumors.
  • BACKGROUND: Defective iron homeostasis may be involved in the development of some diseases within the central nervous system.
  • Although the expression of genes involved in normal iron balance has been intensively studied in other tissues, little is known about their expression in the brain.
  • We investigated the mRNA levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) in normal human brain, brain tumors, and astrocytoma cell lines.
  • The specimens included 5 normal brain tissue samples, 4 meningiomas, one medulloblastoma, 3 oligodendrocytic gliomas, 2 oligoastrocytic gliomas, 8 astrocytic gliomas, and 3 astrocytoma cell lines.
  • In most tumor types, the pattern of gene expression was diverse.
  • Notable findings include high expression of transferrin receptor 1 in the hippocampus and medulla oblongata compared to other brain regions, low expression of HFE in normal brain with elevated HFE expression in meningiomas, and absence of hepcidin mRNA in astrocytoma cell lines despite expression in normal brain and tumor specimens.
  • CONCLUSION: These results indicate that several iron-related genes are expressed in normal brain, and that their expression may be dysregulated in brain tumors.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Histocompatibility Antigens Class I / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / genetics. Antigens, CD / metabolism. Antimicrobial Cationic Peptides / genetics. Antimicrobial Cationic Peptides / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Cell Line, Tumor. Female. GPI-Linked Proteins. Hepcidins. Humans. Male. Meningioma / genetics. Meningioma / metabolism. Middle Aged. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. RNA, Messenger / analysis. Receptors, Transferrin / genetics. Receptors, Transferrin / metabolism. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem Cell Biol. 2001 Mar;115(3):195-203 [11326747.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G590-4 [16537971.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2213-21 [11489794.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Biometals. 2003 Mar;16(1):63-75 [12572665.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Brain Res Bull. 2003 Aug 30;61(4):365-74 [12909279.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 [15122348.001]
  • [Cites] Nat Rev Neurosci. 2004 Nov;5(11):863-73 [15496864.001]
  • [Cites] J Neurosurg. 1990 Jun;72(6):941-5 [2159987.001]
  • [Cites] Nat Genet. 1996 Aug;13(4):399-408 [8696333.001]
  • [Cites] J Comp Neurol. 1996 Nov 25;375(4):675-92 [8930792.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):27-33 [15546588.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Comp Immunol. 2005;29(11):939-50 [15935472.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):33885-94 [16103117.001]
  • [Cites] BMC Neurol. 2006;6:24 [16824219.001]
  • [Cites] J Neurosci Res. 2006 Sep;84(4):790-800 [16933319.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):215-22 [17119289.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):267-76 [17119292.001]
  • [Cites] J Histochem Cytochem. 2007 Jan;55(1):85-96 [16982849.001]
  • [Cites] Eur J Haematol. 2007 Jan;78(1):1-10 [17042775.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1926-32 [17557118.001]
  • [Cites] Retina. 2007 Oct;27(8):997-1003 [18040235.001]
  • [Cites] Blood. 2008 Jan 15;111(2):924-31 [17938254.001]
  • [Cites] Biochemistry. 2008 Apr 8;47(14):4237-45 [18335997.001]
  • [Cites] Cell Metab. 2008 Apr;7(4):288-90 [18396134.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17494-502 [18445598.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):967-75 [18987634.001]
  • [Cites] BMC Cancer. 2005;5:154 [16324219.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • (PMID = 19386095.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antimicrobial Cationic Peptides; 0 / CD71 antigen; 0 / GPI-Linked Proteins; 0 / HAMP protein, human; 0 / HFE protein, human; 0 / HFE2 protein, human; 0 / Hepcidins; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Transferrin; 0 / TFR2 protein, human; 0 / neogenin
  • [Other-IDs] NLM/ PMC2679039
  •  go-up   go-down


22. Miller CR, Dunham CP, Scheithauer BW, Perry A: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol; 2006 Dec 1;24(34):5419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
  • PURPOSE: High-grade gliomas (HGGs; WHO grades 3-4) are highly diverse, with survival times ranging from months to years.
  • WHO 2000 grading criteria for high-grade oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO)] remain subjective, and the existence of grade 4 variants is controversial.
  • PATIENTS AND METHODS: Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery type, year of diagnosis, endothelial proliferation, necrosis, oligodendroglial histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).
  • In addition to patient age, the following were significant independent prognostic factors (P .001): grade and surgery type for the entire HGG cohort; modified grade for AOA (3 v 4); and modified grade, 1p/19q codeletion status, and oligodendroglial histology for the 586 HGGs analyzed by FISH.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Models, Statistical. Multivariate Analysis. Necrosis. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32CA009547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


23. Preusser M, Birner P, Ambros IM, Ambros PF, Budka H, Harris AL, Hainfellner JA: DEC1 expression in 1p-aberrant oligodendroglial neoplasms. Histol Histopathol; 2005 10;20(4):1173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DEC1 expression in 1p-aberrant oligodendroglial neoplasms.
  • BACKGROUND: Expression of hypoxia-related tissue factors in 1p-aberrant oligodendroglial neoplasms diminishes patient outcome.
  • In our study, we assessed the expression of DEC1 in 1p aberrant oligodendroglial neoplasms and its association with necrosis and expression of hypoxia-inducible factor 1alpha (HIF-1alpha), carbonic anhydrase-9 (CA9), and vascular endothelial growth factor-mRNA (VEGF).
  • MATERIALS AND METHODS: 44 primary and 16 recurrent oligodendroglial neoplasms with 1p-aberrations were investigated immunohistochemically for the expression of DEC1, HIF-1alpha, and CA9.
  • RESULTS: DEC1 was expressed in tumor cell nuclei, and occasionally in nuclei of endothelial cells, and glial and neuronal cells of surrounding brain tissue.
  • High expression (>10% of tumor cells immunolabeled) of DEC1 was found in 56 cases, low expression (<10% of tumor cells immunolabeled) was found in 3 cases.
  • CONCLUSION: DEC1 expression is found in the majority of 1p-aberrant oligodendroglial neoplasms and does not correlate with necrosis or expression of HIF-1alpha, CA9, VEGF.
  • Thus, immunohistochemical analysis of DEC1 expression is in our hands not suitable for detection of tissue hypoxia in this type of primary brain tumor.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Tumor Suppressor Proteins / biosynthesis. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Biomarkers. Female. Humans. Hypoxia / diagnosis. Hypoxia / genetics. Hypoxia / pathology. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Male. Necrosis. RNA, Messenger / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136500.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DEC1 protein, human; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


24. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide treatment in patients with high-grade glioma.
  • BACKGROUND: Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • As second- or third-line chemotherapy, patients received TMZ for recurrence or tumor progression.
  • As combination therapy, the local administration of tumor necrosis factor-alpha and the addition of carboplatin and etoposide were included for three patients during the course of oral TMZ treatment.
  • One of the patients receiving combination therapy has continued to show shrinkage of the relapsed tumor.
  • Despite prior radio- and chemotherapy, most patients experienced only grade 1-2 hematotoxicity that was well-controlled by conservative therapy.
  • CONCLUSION: TMZ chemotherapy is effective for the treatment of high-grade glioma in some patients without serious toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


25. Makuria AT, Henderson FC, Rushing EJ, Hartmann DP, Azumi N, Ozdemirli M: Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor. J Neurooncol; 2007 Apr;82(2):199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor.
  • Differentiating oligodendroglioma from extraventricular neurocytoma by conventional light microscopy alone can present a diagnostic challenge.
  • We report pathologic findings of an unusual spinal cord tumor from a 33-year-old male patient which showed hybrid features of oligodendroglioma and extraventricular neurocytoma.
  • Histologic examination revealed a clear cell neoplasm containing ganglion-like cells and calcifications, prompting the differential diagnosis of oligodendroglioma and extraventricular neurocytoma.
  • Molecular studies with fluorescent in situ hybridization (FISH) revealed chromosome 1p/(partial) 19q deletions, a finding commonly observed in oligodendroglioma.
  • The proliferation index (using antibody MIB1) of the tumor was approximately 30%.
  • Because there are differences in patient management and long-term prognosis, it is important to attempt to distinguish between oligodendroglioma and neurocytoma.
  • This unusual case and similar rare reported cases support the need to reclassify tumors showing pathologic features common to both neurocytoma and oligodendroglioma as a unique entity, while the effort continues to identify the cell of origin.
  • [MeSH-major] Neurocytoma / pathology. Oligodendroglioma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1156-9 [15343519.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Apr;32(2):189-202 [16599947.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1606-10 [10193953.001]
  • [Cites] Pathol Int. 2006 Jan;56(1):25-9 [16398676.001]
  • [Cites] Acta Neuropathol. 1994;87(5):537-40 [8059608.001]
  • [Cites] J Neurocytol. 1998 Nov;27(11):805-16 [10451427.001]
  • [Cites] J Neurosurg. 1992 May;76(5):759-65 [1564538.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):47-52 [16078107.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):288-93 [8027814.001]
  • [Cites] Stem Cells. 2005 Mar;23(3):442-53 [15749939.001]
  • [Cites] J Neurosci Res. 1998 Feb 15;51(4):526-35 [9514206.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):1-8 [16078101.001]
  • [Cites] Clin Neuropathol. 2005 Sep-Oct;24(5):225-9 [16167546.001]
  • [Cites] Development. 1988 Nov;104(3):473-82 [3151483.001]
  • [Cites] Neuron. 1991 Oct;7(4):685-93 [1931054.001]
  • [Cites] Nature. 1983 Jun 2-8;303(5916):390-6 [6304520.001]
  • [Cites] Am J Surg Pathol. 1992 Feb;16(2):97-109 [1370756.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):206-12 [9042288.001]
  • [Cites] Ultrastruct Pathol. 1996 Nov-Dec;20(6):537-47 [8940761.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:a1-9 [12456321.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):119 [9221982.001]
  • [Cites] Acta Neuropathol. 1997 Jul;94(1):95-8 [9224537.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1350-5 [12507133.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55 [12430711.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Expert Rev Neurother. 2006 Apr;6(4):519-32 [16623651.001]
  • [Cites] Acta Neuropathol. 1984;64(4):265-72 [6391068.001]
  • [Cites] Histol Histopathol. 1992 Oct;7(4):647-51 [1457988.001]
  • [Cites] Dev Biol. 1997 Jun 15;186(2):202-23 [9205140.001]
  • [Cites] Pathol Res Pract. 2002;198(9):627-33; discussion 635-8 [12440786.001]
  • (PMID = 17039400.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C: Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain; 2006 Jul;129(Pt 7):1884-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
  • Oligodendroglial neoplasms with the -1p/-19q genotype are more indolent with longer survival and increased therapeutic responsiveness than those with intact 1p/19q, but the biological basis for these clinical differences is unclear.
  • Recent research suggests that oligodendrogliomas with and without the -1p/-19q genotype may be distinguished by their magnetic resonance imaging (MRI) appearance, suggesting possible differences in growth characteristics.
  • This study examined the relationship between genotype and histological growth patterns of oligodendroglial neoplasms in association with MR imaging characteristics.
  • Thirty-three oligodendrogliomas (25 with 1p/19q loss) and 53 oligoastrocytomas (18 with 1p/19q loss) were investigated.
  • Solid, mixed or infiltrative growth patterns were seen in grade II and grade III tumours with or without 1p/19q loss, but infiltrative growth was more common in tumours with intact 1p/19q (chi2: P = 0.029).
  • Grade III tumours were more likely to have a solid growth pattern (chi2: P = 0.046) associated with contrast enhancement (chi2: P = 0.011).
  • This study identified a group of oligodendroglial tumours with intact 1p/19q displaying distinctive MR imaging features that were unrelated to the histopathology characteristics.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Allelic Imbalance. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Genotype. Humans. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670176.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


27. Jalali R, Dutta D, Kamble R, Gupta T, Munshi A, Sarin R, Dinshaw K: Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. J Neurooncol; 2008 Dec;90(3):321-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy.
  • PURPOSE: To report prospective evaluations of activities of daily living (ADL) in young patients with low-grade gliomas treated with stereotactic conformal radiotherapy (SCRT).
  • MATERIALS AND METHODS: Between April 2001 and February 2008, 38 children and young adults (age 5-25 years, median 12.5 years) with low-grade gliomas with residual/progressive disease and treated with SCRT were accrued in a prospective protocol.
  • RESULT: The patient population consisted of 38 patients (male 29, female 9) with a diagnosis of residual or progressive low-grade glioma (pilocytic astrocytoma in 27, fibrillary astrocytoma in 5, ependymoma in 4, and oligodendroglioma and pleomorphic xanthoastrocytoma in 1 each).
  • The mean pre-radiotherapy baseline BI of three patients, who eventually developed local recurrence, was only 64 (SD 32.1) as compared with a baseline score of 97.18 seen in patients whose tumor remained controlled at follow-up (P <or= 0.001).
  • CONCLUSIONS: Young patients with low-grade gliomas after surgical intervention had a lower than normal BI before starting radiotherapy, suggesting a decrease in ADL possibly due to tumor- and surgery-related factors.
  • Patients who developed tumor recurrence at follow-up had a significantly lower BI at baseline than patients with controlled disease (P <or= 0.001).
  • [MeSH-major] Activities of Daily Living. Brain Neoplasms / psychology. Brain Neoplasms / radiotherapy. Glioma / psychology. Glioma / radiotherapy. Radiotherapy, Conformal / methods. Stereotaxic Techniques. Surveys and Questionnaires
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prospective Studies. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):273-9 [12796600.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(2):82-6 [7542472.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(1):36-41 [10749018.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]
  • [Cites] Neurosurg Focus. 2000 May 15;8(5):e3 [16859281.001]
  • [Cites] Disabil Rehabil. 2004 Feb 18;26(4):235-45 [15164957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):507-13 [10487578.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):747-53 [2323966.001]
  • [Cites] Radiother Oncol. 2005 Jan;74(1):37-44 [15683667.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3156-62 [15284268.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1348-56; discussion 1356-7 [12762880.001]
  • [Cites] J Clin Epidemiol. 1989;42(8):703-9 [2760661.001]
  • [Cites] QJM. 2003 Sep;96(9):643-8 [12925719.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 Oct;15(7):422-8 [14570092.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):187-92 [9210067.001]
  • [Cites] Brain Inj. 1998 Apr;12(4):283-96 [9562911.001]
  • [Cites] Eur J Cancer Care (Engl). 1995 Jun;4(2):63-8 [7599873.001]
  • [Cites] J Chronic Dis. 1987;40(6):481-9 [3597653.001]
  • [Cites] Medicina (Kaunas). 2006;42(2):130-6 [16528129.001]
  • [Cites] Scand J Caring Sci. 1990;4(3):99-106 [2120762.001]
  • [Cites] Dev Med Child Neurol. 2003 Dec;45(12):821-8 [14667074.001]
  • (PMID = 18704269.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Kobayashi TK, Bamba M, Ueda M, Nishino T, Muramatsu M, Hino A, Shima A, Echigo T, Oka H: Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases. Acta Cytol; 2010 Mar-Apr;54(2):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic diagnosis of central neurocytoma in intraoperative squash preparations: a report of 2 cases.
  • BACKGROUND: Central neurocytoma is a rare central nervous system tumor typically found in the lateral ventricles and at the spectrum pellucidum.
  • Two patients with central neurocytoma underwent intraoperative frozen section diagnoses, and the cytologic evaluations are described.
  • Magnetic resonance imaging (MRI) showed enhancement of a ventricular tumor.
  • Over 80% of the tumor was removed, but after 14 months' follow-up, the disease progressed and regrowth occurred.
  • The patient had a second tumor resection with gamma knife surgery.
  • An MRI showed an enhancement of a ventricular tumor, and complete tumor removal was achieved.
  • In both cases histopathologic examination was consistent with a central neurocytoma.
  • CONCLUSION: These are 2 illustrative cases in which the authors report cytologic evaluation of central neurocytomna in intraoperative preparations.
  • Moreover, it should be emphasized that immunostains for neural markers are essential for distinguishing them from other clear cell tumors of the brain, especially oligodendroglioma and clear cell ependymomal neoplasm.
  • A combination of imaging, cytomorphology and immunohistochemical features of central neurocytoma can help to differentiate this condition from other intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adult. Antigens, Nuclear / metabolism. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / metabolism. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391982.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nerve Tissue Proteins; 0 / Synaptophysin; 0 / neuronal nuclear antigen NeuN, human; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


29. Perry A, Burton SS, Fuller GN, Robinson CA, Palmer CA, Resch L, Bigio EH, Gujrati M, Rosenblum MK: Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. Acta Neuropathol; 2010 Aug;120(2):237-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall.
  • Although oligodendroglial neoplasms are traditionally considered purely glial, increasing evidence suggests that they are capable of neuronal or neurocytic differentiation.
  • Herein, we report seven examples where the primary differential diagnosis was a ganglioglioma with an oligodendroglial component.
  • At presentation, the glial component was oligodendroglioma in six and oligoastrocytoma in one; one was low-grade and six were anaplastic.
  • In contrast to classic ganglioglioma, however, cases lacked eosinophilic granular bodies and CD34-positive tumor cells.
  • We conclude that GGLF represents yet another form of neuronal differentiation in oligodendroglial neoplasms.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioglioma / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neurofilament Proteins / metabolism. Retrospective Studies

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Acta Neuropathol. 2005 Nov;110(5):520-2 [16222523.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Oct;32(5):461-8 [16972880.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):124-34 [17259542.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):199-205 [17039400.001]
  • [Cites] Histopathology. 2007 Jun;50(7):887-96 [17543079.001]
  • [Cites] Semin Ultrasound CT MR. 2008 Feb;29(1):40-6 [18383906.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):360-9 [18371182.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]
  • [Cites] Mol Cancer. 2008;7:41 [18492260.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3355-63 [18988291.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):343-54 [19597701.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Pediatr Neurosurg. 2001 Jun;34(6):301-5 [11455230.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 1;134(1):71-6 [11996800.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 May;61(5):403-12 [12025943.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55 [12430711.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):34-42 [14997935.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1156-9 [15343519.001]
  • [Cites] Histopathology. 1990 Nov;17(5):439-41 [1706300.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neuroscience. 1996 Mar;71(2):601-11 [9053811.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):436-43 [9386775.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] Acta Neuropathol. 1999 May;97(5):481-90 [10334485.001]
  • [Cites] Clin Neuropathol. 2005 Sep-Oct;24(5):225-9 [16167546.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • (PMID = 20464403.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Neurofilament Proteins
  • [Other-IDs] NLM/ PMC2892612
  •  go-up   go-down


30. Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, Henriksson R, Hedman H: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology; 2009 Jun;29(3):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.
  • Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies.
  • The role of LRIG proteins in oligodendroglioma has not previously been studied.
  • Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters.
  • Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival.
  • This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cytoplasm / metabolism. Membrane Glycoproteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / metabolism. Female. Humans. Kaplan-Meier Estimate. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992012.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / LRIG1 protein, human; 0 / LRIG2 protein, human; 0 / LRIG3 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins
  •  go-up   go-down


31. Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, Aldape KD, Gilbert MR, Bondy M: Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer; 2010 May 1;116(9):2242-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype.
  • CONCLUSIONS: In patients with anaplastic oligodendroglial tumors, the GSTT1 null genotype may be associated with poor survival, possibly because of modifications in therapy secondary to increased toxicity.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2358-62 [10344744.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2175-9 [15788664.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4749-53 [16000570.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5552-9 [16110016.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):231-6 [16328000.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):441-7 [16342067.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):281-6 [16317430.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3050-6 [16707601.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):708-14 [17228018.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1222-8 [10666194.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):11-9 [10866345.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):258-62 [11071881.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Pharmacogenetics. 2000 Nov;10(8):715-26 [11186134.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1279-87 [11230469.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7130-5 [11585745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Leukemia. 2002 Feb;16(2):203-8 [11840286.001]
  • [Cites] Blood. 2002 Jul 1;100(1):67-71 [12070010.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):936-42 [12072547.001]
  • [Cites] Pharmacogenetics. 2002 Oct;12(7):543-53 [12360105.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):527-33 [12814998.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1463-72 [15368334.001]
  • [Cites] Am J Hum Genet. 1981 Jan;33(1):36-43 [7468592.001]
  • [Cites] Semin Oncol. 1986 Mar;13(1):38-45 [3513316.001]
  • [Cites] CRC Crit Rev Biochem. 1988;23(3):283-337 [3069329.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6976-80 [2208164.001]
  • [Cites] Biochem J. 1991 Mar 1;274 ( Pt 2):409-14 [1848757.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4257-61 [8395980.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10004-12 [9092542.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):397-402 [9299520.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2253-61 [9815622.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 1;366(1):89-94 [10334868.001]
  • [Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]
  • (PMID = 20187096.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094746-02; United States / NCI NIH HHS / CA / R03 CA094746; United States / NCI NIH HHS / CA / 1R03CA094746; United States / NCI NIH HHS / CA / R03 CA094746-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase
  • [Other-IDs] NLM/ NIHMS189687; NLM/ PMC2861043
  •  go-up   go-down


32. Tie Y, Whalen S, Suarez RO, Golby AJ: Group independent component analysis of language fMRI from word generation tasks. Neuroimage; 2008 Sep 1;42(3):1214-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Language fMRI has been used to study brain regions involved in language processing and has been applied to pre-surgical language mapping.
  • Type II error of failing to reach statistical significance when the language activations are genuinely present may be particularly relevant to pre-surgical planning, by falsely indicating low surgical risk in areas where no activations are shown.
  • We specifically investigated whether this approach might reduce type II error as well as generate more language-specific maps.
  • Encouraging results from one brain tumor patient are also presented.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroimage. 2002 Jul;16(3 Pt 1):551-63 [12169242.001]
  • [Cites] Neuropsychol Rev. 2007 Jun;17(2):145-55 [17484055.001]
  • [Cites] Hum Brain Mapp. 2003 Feb;18(2):111-22 [12518291.001]
  • [Cites] Neuroimage. 2003 Jul;19(3):1233-9 [12880848.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):699-701 [12963768.001]
  • [Cites] Neuroimage. 2003 Dec;20(4):2142-52 [14683718.001]
  • [Cites] J Magn Reson Imaging. 2004 Mar;19(3):365-8 [14994306.001]
  • [Cites] Neuroimage. 2004 Jul;22(3):1414-20 [15219612.001]
  • [Cites] Science. 1990 Aug 31;249(4972):1041-4 [2396097.001]
  • [Cites] J Neuroimaging. 1994 Apr;4(2):67-70 [8186531.001]
  • [Cites] Neural Comput. 1995 Nov;7(6):1129-59 [7584893.001]
  • [Cites] Neurology. 1996 Apr;46(4):978-84 [8780076.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):353-62 [8987760.001]
  • [Cites] J Cogn Neurosci. 2000 Jan;12(1):1-47 [10769304.001]
  • [Cites] Hum Brain Mapp. 2000 Jul;10(3):120-31 [10912591.001]
  • [Cites] Neural Netw. 2000 May-Jun;13(4-5):411-30 [10946390.001]
  • [Cites] Hum Brain Mapp. 2007 Nov;28(11):1251-66 [17274023.001]
  • [Cites] Hum Brain Mapp. 2008 Dec;29(12):1450-61 [17990304.001]
  • [Cites] Hum Brain Mapp. 2001 Nov;14(3):140-51 [11559959.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Oct;22(9):1711-8 [11673166.001]
  • [Cites] Neuroimage. 2001 Nov;14(5):1080-8 [11697939.001]
  • [Cites] Epilepsia. 2001 Oct;42(10):1241-54 [11737158.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jan;23(1):49-58 [11827875.001]
  • [Cites] Neuroimage. 2002 Apr;15(4):823-35 [11906223.001]
  • [Cites] Clin Neurosci. 1997;4(2):87-94 [9059758.001]
  • [Cites] Neurosurg Clin N Am. 1997 Jul;8(3):383-92 [9188545.001]
  • [Cites] Neuroimage. 1997 May;5(4 Pt 1):261-70 [9345555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):803-10 [9448244.001]
  • [Cites] Neuroimage. 1999 Jul;10(1):15-35 [10385578.001]
  • [Cites] Magn Reson Imaging. 2004 Nov;22(9):1181-91 [15607089.001]
  • [Cites] Magn Reson Imaging. 2004 Dec;22(10):1493-504 [15707799.001]
  • [Cites] Neuroimage. 2005 Mar;25(1):193-205 [15734355.001]
  • [Cites] Neuroimage. 2005 Mar;25(1):294-311 [15734364.001]
  • [Cites] Neuroimage. 2005 Apr 15;25(3):653-60 [15808966.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2005 May 29;360(1457):1001-13 [16087444.001]
  • [Cites] Neuroimage. 2006 Jan 1;29(1):254-66 [16109491.001]
  • [Cites] Hum Brain Mapp. 2006 May;27(5):392-401 [16596654.001]
  • [Cites] Neuroimage. 2007 Mar;35(1):131-9 [17208459.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4 Suppl 2):185-201; discussion 201-2 [17415154.001]
  • [Cites] Radiology. 2007 Jun;243(3):828-36 [17517936.001]
  • [Cites] Science. 2002 Sep 6;297(5587):1706-8 [12215648.001]
  • (PMID = 18621548.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703-045853; United States / NINDS NIH HHS / NS / NS048063-04; United States / NCRR NIH HHS / RR / RR019703-045853; United States / NCRR NIH HHS / RR / U41 RR019703-01A29003; United States / NINDS NIH HHS / NS / NS048063-02; United States / NCRR NIH HHS / RR / RR019703-028713; United States / NCRR NIH HHS / RR / U41 RR019703; United States / NCRR NIH HHS / RR / RR019703-056997; United States / NINDS NIH HHS / NS / K08 NS048063-02; United States / NINDS NIH HHS / NS / K08 NS048063; United States / NCRR NIH HHS / RR / RR019703-01A29003; United States / NINDS NIH HHS / NS / K08 NS048063-03; United States / NCRR NIH HHS / RR / U41 RR019703-056997; United States / NCRR NIH HHS / RR / RR019703-037948; United States / NCI NIH HHS / CA / P01 CA067165-10; United States / NINDS NIH HHS / NS / NS048063-05; United States / NCRR NIH HHS / RR / U41 RR019703-037948; United States / NINDS NIH HHS / NS / K08 NS048063-04; United States / NINDS NIH HHS / NS / NS048063-03; United States / NCRR NIH HHS / RR / U41 RR019703-028713; United States / NINDS NIH HHS / NS / K08 NS048063-01; United States / NINDS NIH HHS / NS / K08 NS048063-05; United States / NCI NIH HHS / CA / P01 CA067165; United States / NINDS NIH HHS / NS / NS048063-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS67198; NLM/ PMC2598840
  •  go-up   go-down


33. Taal W, van der Rijt CD, Sillevis Smitt PA, Kros JM, van Heuvel I, Enting RH, van den Bent MJ: [Favourable result for temozolomide in recurrent high-grade glioma]. Ned Tijdschr Geneeskd; 2005 Jun 18;149(25):1393-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Favourable result for temozolomide in recurrent high-grade glioma].
  • METHOD: This study evaluated 77 patients with a recurrent high-grade glioma who from August 1997-December 2003 were treated with temozolomide (150-200 mg/m2/day for 5 days per 28-day cycle) following surgery and radiotherapy at the Daniel den Hoed Oncology Centre of the Erasmus MC, Rotterdam, the Netherlands.
  • RESULTS: 15 patients received temozolomide for a recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • 35 patients underwent second-line chemotherapy with temozolomide after earlier chemotherapy with procarbazine, lomustine and vincristine for recurrent anaplastic oligodendroglioma or mixed oligo-astrocytoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1376-8 [15997689.001]
  • (PMID = 15997692.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


34. Talos IF, Zou KH, Ohno-Machado L, Bhagwat JG, Kikinis R, Black PM, Jolesz FA: Supratentorial low-grade glioma resectability: statistical predictive analysis based on anatomic MR features and tumor characteristics. Radiology; 2006 May;239(2):506-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial low-grade glioma resectability: statistical predictive analysis based on anatomic MR features and tumor characteristics.
  • PURPOSE: To retrospectively assess the main variables that affect the complete magnetic resonance (MR) imaging-guided resection of supratentorial low-grade gliomas.
  • Data from 101 patients (61 men, 40 women; mean age, 39 years; age range, 18-72 years) who had nonenhancing supratentorial mass lesions that were histopathologically diagnosed as low-grade (World Health Organization grade II) gliomas and consecutively underwent surgery with intraoperative MR imaging guidance were analyzed.
  • There were 21 low-grade astrocytomas, 64 oligodendrogliomas, and 16 mixed oligoastrocytomas.
  • Initial and residual tumor volumes were measured on intraoperative T2-weighted MR images and three-dimensional spoiled gradient-echo MR images.
  • The anatomic relationships between the tumor and eloquent cortical and/or subcortical regions and the influence of these relationships on the extent of resection were analyzed on the basis of preoperative MR imaging findings.
  • RESULTS: Tumor volume ranged from 2.7-231.0 mL.
  • Univariate analyses revealed the following tumor characteristics to be significant predictive variables of incomplete tumor resection: diffuse tumor margin on T2-weighted MR images, oligodendroglioma or oligoastrocytoma histopathologic type, and large tumor volume (P < .05 for all).
  • Tumor involvement of the following structures was associated with incomplete resection: corpus callosum, corticospinal tract, insular lobe, middle cerebral artery, motor cortex, optic radiation, visual cortex, and basal ganglia (P < .05 for all).
  • Multivariate analyses revealed that incomplete tumor resection was due to tumor involvement of the corticospinal tract (P < .01), large tumor volume (P < .01), and oligodendroglioma histopathologic type (P = .02).
  • CONCLUSION: The main variables associated with incomplete tumor resection in 101 patients were identified by using statistical predictive analyses.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2006.
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Neurosurgery. 2000 Nov;47(5):1070-9; discussion 1079-80 [11063099.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):89-98 [11158893.001]
  • [Cites] Eur Radiol. 2001;11(2):309-16 [11218033.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):787-97; discussion 797-8 [11322439.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):967-75 [11382961.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Neurosurgery. 2001 Dec;49(6):1313-20; discussion 1320-1 [11846930.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):377-80 [11891834.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):568-75 [12296640.001]
  • [Cites] J Clin Neurosci. 2003 Jan;10(1):1-13 [12464515.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):468-80 [12489096.001]
  • [Cites] Acta Neurochir Suppl. 2003;85:55-63 [12570138.001]
  • [Cites] Radiology. 2003 Jun;227(3):617-22 [12773666.001]
  • [Cites] Radiology. 2003 Oct;229(1):3-8 [14519861.001]
  • [Cites] Acad Radiol. 2003 Dec;10(12):1359-68 [14697004.001]
  • [Cites] Radiology. 2004 Feb;230(2):504-9 [14699179.001]
  • [Cites] Radiology. 2004 May;231(2):517-27 [15044743.001]
  • [Cites] Neurosurgery. 2004 Aug;55(2):358-70; discussion 370-1 [15271242.001]
  • [Cites] Radiology. 2004 Sep;232(3):685-92 [15215551.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Radiology. 1983 Sep;148(3):839-43 [6878708.001]
  • [Cites] Pediatr Neurol. 1988 Sep-Oct;4(5):279-83 [3242530.001]
  • [Cites] Surg Neurol. 1993 Jun;39(6):458-65 [8390726.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):678-84; discussion 684-5 [8692384.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):253-8; discussion 258-9 [8832661.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):85-101 [9210055.001]
  • [Cites] Chest. 1999 Mar;115(3):714-9 [10084481.001]
  • (PMID = 16641355.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41-RR13218; United States / NLM NIH HHS / LM / R01-LM007861; United States / NCRR NIH HHS / RR / P41 RR019703; United States / NLM NIH HHS / LM / R01 LM007861; United States / NCRR NIH HHS / RR / P41-RR019703; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NCI NIH HHS / CA / P01CA67165; United States / NCI NIH HHS / CA / P01 CA067165
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS9769; NLM/ PMC1475754
  •  go-up   go-down


35. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science; 2009 Apr 10;324(5924):261-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown.
  • We have shown that tumor-derived IDH1 mutations impair the enzyme's affinity for its substrate and dominantly inhibit wild-type IDH1 activity through the formation of catalytically inactive heterodimers.
  • Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product, alpha-ketoglutarate (alpha-KG), and increases the levels of hypoxia-inducible factor subunit HIF-1alpha, a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by alpha-KG.
  • Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Biocatalysis. Cell Line. Child. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / metabolism. Humans. Ketoglutaric Acids / metabolism. Male. Middle Aged. Mutant Proteins / chemistry. Mutant Proteins / metabolism. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oxalates / pharmacology. Protein Multimerization


36. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB: Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res; 2008 Dec 1;14(23):7717-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
  • PURPOSE: As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential.
  • Here, we investigate the role of PDE4 in brain tumors and examine the utility of PDE4 as a therapeutic target.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was used to evaluate the expression pattern of a subfamily of PDE4, PDE4A, in multiple brain tumor types.
  • To evaluate the effect of PDE4A on growth, a brain-specific isoform, PDE4A1 was overexpressed in xenografts of Daoy medulloblastoma and U87 glioblastoma cells.
  • RESULTS: We found that PDE4A is expressed in medulloblastoma, glioblastoma, oligodendroglioma, ependymoma, and meningioma.
  • Bioluminescence imaging indicated that whereas temozolomide and radiation therapy arrested intracranial tumor growth, the addition of Rolipram to this regimen resulted in tumor regression.
  • CONCLUSIONS: This study shows that PDE4 is widely expressed in brain tumors and promotes their growth and that inhibition with Rolipram overcomes tumor resistance and mediates tumor regression.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11392-9 [16357147.001]
  • [Cites] Drug Discov Today. 2005 Nov 15;10(22):1503-19 [16257373.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1666-78 [16478988.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):733-54 [16759164.001]
  • [Cites] Biochem Soc Trans. 2006 Aug;34(Pt 4):504-9 [16856845.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3799-810 [16940352.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] Curr Top Dev Biol. 2006;75:225-59 [16984814.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5248-57 [17545604.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Chem Res Toxicol. 2000 Oct;13(10):944-8 [11080038.001]
  • [Cites] Cell Signal. 2001 Dec;13(12):911-8 [11728831.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28298-309 [11994273.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):477-83 [191576.001]
  • [Cites] J Neurooncol. 1983;1(1):61-7 [6086852.001]
  • [Cites] Pharmacopsychiatry. 1984 Nov;17(6):188-90 [6393150.001]
  • [Cites] Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 [7686364.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):673-81 [7772057.001]
  • [Cites] Eur J Cancer. 1995;31A(5):714-7 [7640043.001]
  • [Cites] Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 [7575434.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):161-8 [9120546.001]
  • [Cites] Neurosci Lett. 1998 Mar 6;244(1):41-6 [9578140.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):693-703 [9677330.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4733-43 [9822544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Cell Signal. 2005 Sep;17(9):1158-73 [15905070.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1523-31 [16034090.001]
  • [Cites] Arch Toxicol. 2006 Feb;80(2):88-97 [16167140.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):607-14 [16094386.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33178-89 [16030021.001]
  • [CommentIn] Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9 [19406836.001]
  • (PMID = 19047098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R21 CA108677; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / P50 CA094056-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phosphodiesterase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram
  • [Other-IDs] NLM/ NIHMS82831; NLM/ PMC2615415
  •  go-up   go-down


37. Xia Z, Zhang N, Jin H, Yu Z, Xu G, Huang Z: Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas. Clin Neurol Neurosurg; 2010 Jun;112(5):413-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas.
  • OBJECTIVE: To investigate the expression of astrocyte elevated gene-1 (AEG-1) in human oligodendrogliomas and the association between AEG-1 expression and progression of oligodendrogliomas.
  • METHODS: The expression of AEG-1 in normal human oligodendroglial cells, oligodendroglioma cell line, and four pairs of matched oligodendroglioma tissues and their adjacent normal brain tissues was detected by quantitative RT-PCR and western blotting.
  • In addition, AEG-1 protein expression was examined in 75 cases of histologically characterized oligodendrogliomas by immunohistochemistry.
  • RESULTS: Western blotting and RT-PCR showed that AEG-1 mRNA and protein were elevated in the oligodendroglioma cell line and significantly upregulated in primary oligodendrogliomas compared with the adjacent non-cancerous brain tissues.
  • Immunohistochemical analysis showed that 51 of 75 (68.0%) paraffin-embedded archival oligodendroglioma samples exhibited high expression of AEG-1.
  • Statistical analysis suggested that upregulation of AEG-1 was significantly correlated with the histological grade of oligodendroglioma (p=0.000) and that patients with high AEG-1 level exhibited shorter survival time (p=0.000).
  • Multivariate analysis revealed that AEG-1 upregulation might be an independent prognostic indicator for the survival of patients with oligodendroglioma.
  • CONCLUSIONS: AEG-1 might represent a novel, useful diagnostic and prognostic marker for oligodendroglioma and play a role during the development and progression of the disease.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Adhesion Molecules / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Blotting, Western. DNA Primers / genetics. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20236756.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / Ki-67 Antigen; 0 / MTDH protein, human; 0 / RNA, Messenger
  •  go-up   go-down


38. Razzaq AA, Akula M, Mathew B: Unusual recurrence of pleomorphic xanthoastrocytoma. Br J Neurosurg; 2006 Dec;20(6):433-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439101.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Johansson FK, Göransson H, Westermark B: Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene; 2005 Jun 2;24(24):3896-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice.
  • Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice.
  • In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors.
  • Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendroglioma (OD) and had 2.3 insertions per tumor.
  • Several known and novel genes of tumor progression or cell markers were differentially expressed between OD- and GBM-like tumors.
  • Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfralpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Mutagenesis, Insertional. Retroviridae / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750623.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Neoplasm; 0 / platelet-derived growth factor BB
  •  go-up   go-down


40. Molinari C, Iorio P, Medri L, Ballardini M, Guiducci G, Cremonini AM, Cerasoli S, Riccioni L, Faedi M, Mariani GA, Zoli W, Silvestrini R, Calistri D: Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study. Int J Mol Med; 2010 Jan;25(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.
  • Oligodendrogliomas are rare primary brain tumors with variable patient outcomes which are not always adequately accounted for by clinical or pathological variables.
  • The present study evaluated the prognostic implications of chromosome 1p and 19q status in a set of 23 low grade oligodendrogliomas (OGD II), and correlated the results with patient outcome.
  • Our results showed that the molecular alterations are associated with age and tumor localization.
  • Further studies are now ongoing to determine whether this methodological approach could be potentially useful in low grade oligodendrogliomas to better characterize chromosomal alterations of 1p/19q and identify subgroups of patients with a higher risk of disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956913.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


41. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer; 2005 Jun 15;103(12):2606-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
  • BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS).
  • The osmotic blood-brain barrier disruption (BBBD) procedure is one such strategy, and has been studied extensively in preclinical and clinical studies.
  • The authors detail their experience so far with the procedure in the context of an open Phase II study in the treatment of malignant brain tumors.
  • METHODS: Patients with histologically proven malignant gliomas, primitive neuroectodermal tumors, primary CNS lymphomas, and metastatic disease to the brain were eligible.
  • The overall median survival times (MST) from treatment initiation for glioblastoma multiforme (GBM), anaplastic oligodendrogliomas, primary CNS lymphomas, and metastases were, respectively, 9.1, 13.9, not reached, and 9.9 months, whereas time to disease progression was 4.1, 9.2, 12.3, and 3.3 months.
  • CONCLUSIONS: These encouraging results prompted the authors to further refine their knowledge of the potential contribution of this procedure in the treatment of brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Infusions, Intra-Arterial. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Disease Progression. Drug Delivery Systems. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Lymphoma / drug therapy. Lymphoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Vittal NB, Singh P, Azar NJ: Ictal flatulence: seizure onset in the nondominant hemisphere. Epilepsy Behav; 2009 Dec;16(4):663-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This localization was supported by structural brain imaging showing recurrence of a right frontotemporal oligodendroglioma with involvement of the insula.
  • [MeSH-minor] Adult. Autonomic Nervous System Diseases / complications. Autonomic Nervous System Diseases / diagnosis. Electroencephalography. Female. Functional Laterality. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Gas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846345.001).
  • [ISSN] 1525-5069
  • [Journal-full-title] Epilepsy & behavior : E&B
  • [ISO-abbreviation] Epilepsy Behav
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ribom D, Smits A: Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas. Neurol Res; 2005 Jul;27(5):516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas.
  • OBJECTIVES: The aim of the present study was to assess the usefulness of positron emission tomography (PET) with the amino acid tracer 11C-methionine (MET) as a predictor of time to progression (TTP) in patients with supratentorial grade 2 gliomas.
  • METHODS: Twenty-seven patients with glioma grade 2 subjected to a baseline PET scan received no anti-tumour treatment except for a diagnostic operation, and were followed until tumour progression.
  • Low uptake of MET was a predictor for long TTP in patients with oligodendrogliomas (p = 0.04) but not in astrocytomas/oligoastrocytomas.
  • Other predictors for long TTP were oligodendroglioma histology (p = 0.009) and seizures as presenting symptom (p = 0.03).
  • Favourable prognostic factors for overall survival were oligodendroglioma histology (p = 0.002) and good performance status (p = 0.03).
  • CONCLUSIONS: PET MET has a definite role in the therapeutic management of grade 2 gliomas.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Methionine. Oligodendroglia / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978178.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


44. Smits A, Savitcheva I, Ribom D: [MET-PET in low-grade glioma. Safe way to follow disease progression and treatment]. Lakartidningen; 2007 Jan 31-Feb 6;104(5):326-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MET-PET in low-grade glioma. Safe way to follow disease progression and treatment].
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Astrocytoma / mortality. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Disease Progression. Humans. Oligodendroglioma / mortality. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / radiotherapy. Prognosis. Randomized Controlled Trials as Topic. Risk Factors


45. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben-Hassel M, Guegan Y: Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus; 2005 Nov;19(5):E15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies.
  • OBJECT: Demonstration of the loss of chromosomes 1p and 19q in the presence of a brain neoplasm marks the emergence of genotype as a prognostic indicator.
  • The authors report gene expression data for oligodendroglioma and correlate genotype with response to therapy.
  • METHODS: Eighty-seven cases of supratentorial oligodendroglioma were selected from 145 cases treated in a single center between January 1990 and December 2001.
  • Three molecular subtypes emerged: oligodendroglioma with 1p and 19q deletions, oligodendroglioma demonstrating polysomia and a lack of meaningful response to radiotherapy or chemotherapy, and oligodendroglioma with no 1p-9q deletion in which partial response was seen.
  • CONCLUSIONS: According to our data, oligodendrogliomas could be divided into three molecular subtypes.
  • Although chemotherapy seems efficient for managing this tumor, additional studies should be conducted to compare the efficacy of radiotherapy and chemotherapy.
  • [MeSH-major] Chromosome Aberrations. Oligodendroglioma / epidemiology. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Confidence Intervals. Female. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398465.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S: Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med; 2005 Dec;19(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.
  • If the degree of malignancy of brain tumors can be evaluated by MET-PET, the usefulness of MET-PET as a means of diagnosing brain tumors will increase.
  • Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.
  • Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.
  • The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.
  • Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).
  • The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).
  • CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.
  • The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Glioma / pathology. Glioma / radionuclide imaging. Methionine / pharmacokinetics. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Image Interpretation, Computer-Assisted / methods. Male. Middle Aged. ROC Curve. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution


47. Bristol RE: Low-grade glial tumors: are they all the same? Semin Pediatr Neurol; 2009 Mar;16(1):23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade glial tumors: are they all the same?
  • The most common diagnosis for supratentorial brain tumors in children is a form of low-grade glioma.
  • Even though the numbers of any given tumor type are small, the question has been raised as to whether different pathologies require different treatments.
  • We reviewed the published articles on treatment and outcomes for all pathologies included under the heading "low-grade glioma" to answer this question.
  • The only pathologic subgroups that may benefit from more aggressive up-front treatment are the grade II astrocytomas.
  • Although the data from adult radiosurgical studies are promising, data for the pediatric population are not yet available.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / therapy. Chemotherapy, Adjuvant. Child. Ganglioglioma / diagnosis. Ganglioglioma / therapy. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410153.001).
  • [ISSN] 1558-0776
  • [Journal-full-title] Seminars in pediatric neurology
  • [ISO-abbreviation] Semin Pediatr Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


48. Chan DT, Poon WS, Chan YL, Ng HK: Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J; 2005 Dec;11(6):452-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology reviewed by a neuropathologist was required to show anaplastic glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed anaplastic oligoastrocytoma) or glioblastoma multiforme.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340021.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


49. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP: Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol; 2005 Feb;26(2):266-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
  • BACKGROUND AND PURPOSE: Histopathologic evaluation remains the reference standard for diagnosis of glioma and classification of histologic subtypes, but is challenged by subjective criteria, tissue sampling error, and lack of specific tumor markers.
  • The purpose of our study was to investigate dynamic susceptibility contrast-enhanced (DSC) MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma: astrocytoma and oligodendroglioma.
  • We hypothesized that tumor blood-volume measurements, derived from DSC MR imaging, would help differentiate the two on the basis of differences in tumor vascularity.
  • METHODS: We studied 25 consecutive patients with treatment-naive, histopathologically confirmed World Health Organization grade II astrocytoma (n = 11) or oligodendroglioma (n = 14).
  • RESULTS: The maximum relative CBV (rCBV(max)) in tumor ranged from 0.48 to 1.34 (0.92 +/- 0.27, median +/- SD) in astrocytomas and from 1.29 to 9.24 (3.68 +/- 2.39) in oligodendrogliomas.
  • The difference in median rCBV(max) between the two tumor types was significant (P < .0001).
  • CONCLUSION: The tumor rCBV(max) measurements derived from DSC MR imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas.
  • Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Blood Volume. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709123.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS 45013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


50. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report.
  • BACKGROUND: As in all diffuse gliomas, recurrence is an inherent feature of oligodendrogliomas, either as the same or higher grade neoplasm at the primary site.
  • The rate of remote recurrence after surgery for the primary tumor cannot be estimated from the scarce literature, but delayed treatment of the primary tumor and genetic alterations may be associated with this phenomenon.
  • A magnetic resonance imaging scan disclosed a right frontal mass lesion showing features of a low-grade glioma for which he refused any treatment.
  • Seven months after diagnosis upon uncontrollable seizures, he underwent a stereotactic biopsy, which was followed by a right frontal craniotomy, both of which confirmed the lesion as a grade 2 oligodendroglioma.
  • CONCLUSION: Recurrence of a frontal lobe oligodendroglioma remote from the primary site as a GBM is a rare occurrence.
  • As the genetic analysis suggests, conversion of oligodendroglioma to GBM may be associated with gain of chromosome 7, loss of chromosome 10, and other genetic markers that may represent late events in the oncogenesis of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, Takanami K, Takai Y, Tominaga T: Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog. J Neurosurg; 2010 Aug;113(2):358-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Assessment of hypoxic conditions in brain tumors is important for predicting tumor aggressiveness and treatment response.
  • METHODS: The FRP-170 was injected and PET imaging was performed 2 hours later in 8 patients, including 3 with glioblastoma multiforme, 2 with oligodendroglioma, and 1 each with diffuse astrocytoma, anaplastic ganglioglioma, and recurrent anaplastic astrocytoma.
  • RESULTS: The FRP-170 PET images showed marked uptake with upregulation of HIF-1alpha in the 3 glioblastomas multiforme, and moderate uptake in the recurrent anaplastic astrocytoma and one oligodendroglioma, but no uptake in the other tumors.
  • This new method can assess tumor hypoxia preoperatively and noninvasively.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Glioblastoma / radionuclide imaging. Hypoxia, Brain / radionuclide imaging. Nitroimidazoles. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Biopsy. Carbon Isotopes. Cell Division. Female. Fluorodeoxyglucose F18. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Methionine. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Protons. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895196.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / FRP-170; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 0 / Protons; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


52. Sankar T, Kuznetsov YE, Ryan RW, Caramanos Z, Antel SB, Arnold DL, Preul MC: The metabolic epicenter of supratentorial gliomas: a 1H-MRSI study. Can J Neurol Sci; 2009 Nov;36(6):696-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We approached the problem using multivoxel proton magnetic resonance spectroscopic imaging (1H-MRSI) to define a tumor "metabolic epicenter", and examined the relationship of metabolic epicenter location to survival and histopathological grade.
  • METHODS: We studied 54 consecutive patients with a supratentorial glioma (astrocytoma or oligodendroglioma, WHO grades II-IV).
  • The metabolic epicenter in each tumor was defined as the 1H-MRSI voxel containing maximum intra-tumoral choline on preoperative imaging.
  • Tumor location was considered the X-Y-Z coordinate position, in a standardized stereotactic space, of the metabolic epicenter.
  • Correlation between epicenter location and survival or grade was assessed.
  • A predictive model based on both metabolic epicenter location and histopathological grade accounted for 70% of the variability in survival, substantially improving on histology alone to predict survival.
  • Location also correlated significantly with grade (r2 = 0.25, p = 0.001): higher grade tumors had a metabolic epicenter closer to the midpoint of the brain.
  • The location of the metabolic epicenter is strongly correlated with overall survival and histopathological grade, suggesting that it reflects biological factors underlying glioma growth and malignant dedifferentiation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Aspartic Acid / metabolism. Chi-Square Distribution. Choline / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Proportional Hazards Models. Protons. Retrospective Studies. Tomography, X-Ray Computed / methods. Young Adult

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960747.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; N91BDP6H0X / Choline
  •  go-up   go-down


53. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • PURPOSE: Allelic loss at 1p is seen in 70% to 85% of oligodendrogliomas (typically in association with 19q allelic loss) and 20-30% of astrocytomas.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • RESULTS: Allelic losses on 1p and 19q, either separately or combined, were more common in classic oligodendrogliomas than in either astrocytomas or oligoastrocytomas (P < 0.0001).
  • Classic oligodendrogliomas showed 1p loss in 35 of 42 (83%) cases, 19q loss in 28 of 39 (72%), and these were combined in 27 of 39 (69%) cases.
  • There was no significant difference in 1p/19q LOH status between low-grade and anaplastic oligodendrogliomas.
  • Although rare, 1p deletions were more often segmental in astrocytomas (5 of 6, 83%) than in oligodendrogliomas (3 of 35, 9%; P = 0.006).
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • CAMTA1 is normally expressed predominantly in non-neoplastic adult brain tissue.
  • Relative to the latter, the expression level of CAMTA1 was low in oligodendroglial tumors and was further halved in cases with 1p deletion compared with those without 1p deletion (Mann-Whitney, P = 0.03).
  • CONCLUSIONS: Our data confirm the strong association of combined 1p/19q loss with classic oligodendroglioma histology and identify a very small segment of 1p36 located within CAMTA1 that was deleted in all oligodendroglial tumors with 1p LOH.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


54. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer: Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol; 2007 Dec 20;25(36):5723-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
  • PURPOSE: Little is known about the health-related quality of life (HRQOL) of patients treated for anaplastic oligodendrogliomas.
  • PATIENTS AND METHODS: Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy.
  • HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module.
  • [MeSH-major] Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 20;26(12):2061-2; author reply 2062 [18421064.001]
  • (PMID = 18089866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


55. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F: Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Neuro Oncol; 2010 May;12(5):490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
  • The purpose of this study was to determine whether chromosome 10q loss is a predictor of tumor aggressiveness and poor clinical outcome in patients with oligodendroglial tumors alone or together with loss of heterozygosity (LOH) on chromosomes 1p and 19q.
  • A microsatellite analysis was performed on sections from 130 patients with grade II and grade III oligodendroglial tumors to assess the allelic status of chromosomes 1p, 19q, and 10q, plus detailed clinical and radiological information was taken prospectively.
  • Age <47 years, postoperative Karnofsky performance score >65, no contrast enhancement on MRI, grade II, and complete removal on surgery were significantly correlated with a better PFS.
  • Pure oligodendroglioma and temozolomide chemotherapy were correlated with better OS.
  • 10q LOH was correlated with anaplastic grade and 1p19q LOH correlated with pure oligodendroglioma.
  • 10q LOH predicted a survival disadvantage in patients with oligodendroglial tumors irrespective of 1p/19q LOH status.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Precision Medicine / methods. Prognosis. Young Adult


56. Daumas-Duport C, Koziak M, Miquel C, Nataf F, Jouvet A, Varlet P: [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].
  • [Transliterated title] Classification des oligodendrogliomes de l'hôpital Sainte-Anne. Mise au point à l'usage des études rétrospectives.
  • PURPOSE: Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions.
  • PATIENTS AND METHODS: This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003.
  • Routine histological preparations and post-contrast preoperative MRI/CT-scan were simultaneously reviewed in order to assess the impact on survival of the following features: presence or absence of a polymorphous or gemistocytic astrocytic component, of necrosis and of contrast enhancement (CH); endothelial hyperplasia (EH) assessed as absent, present minor (HE+) or (HE++) when conform to the threshold of HE defined in the SA grading system of oligodendrogliomas.
  • RESULTS: 70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma".
  • In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis.
  • After regrouping of the histological subtypes and of the tumors with HE+ or absent, the series included 153 oligodendrogliomas grade A and 98 grade B.
  • Survival in patients with grade A versus grade B tumors was respectively 142 versus 52 months (p<0.0001).
  • In grade B tumors, necrosis had no significant influence on survival.
  • On post contrast MRI done in 235 patients, only 7 tumors (3%) were grade A/B (EH++ but no CH).
  • CONCLUSIONS: From these results and our previous observation that, according to the SA classification of gliomas, only oligodendrogliomas or oligo-astrocytomas may not show CE, we propose that for retrospective studies:.
  • 1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.
  • [MeSH-major] Brain / pathology. Brain / radiography. Brain Neoplasms / classification. Glioma / classification. Oligodendroglioma / classification
  • [MeSH-minor] Adult. France. Hospitals. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292168.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


57. Panesar NK, Sidhu JS: Uterine cervical teratoma with divergent neuroepithelial differentiation and development of an oligodendroglioma: report of a case and review of the literature. Ann Diagn Pathol; 2007 Aug;11(4):293-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine cervical teratoma with divergent neuroepithelial differentiation and development of an oligodendroglioma: report of a case and review of the literature.
  • A uterine cervical teratoma with divergent neuroepithelial differentiation and/or development of a neurological tumor has never been reported.
  • We describe a case of uterine cervical teratoma exhibiting ectodermal, endodermal, mesodermal, and various types of neuroepithelial differentiation and development of a small oligodendroglioma in a 38-year-old female.
  • The presence of immature neuroepithelium defines this teratoma as immature, and the development of a low-grade malignant neoplasm from one of its components makes it malignant.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Oligodendroglioma / pathology. Teratoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome


58. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE: Salvage temozolomide for prior temozolomide responders. Cancer; 2005 Dec 1;104(11):2473-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age of the patients was 56 years (range, 25-67 yrs) at the time of diagnosis; 9 patients had glioblastoma, 3 had anaplastic astrocytoma, and 2 patients had low-grade oligodendroglioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Oligodendroglioma / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270316.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


59. Ducray F, Dutertre G, Ricard D, Gontier E, Idbaih A, Massard C: [Advances in adults' gliomas biology, imaging and treatment]. Bull Cancer; 2010 Jan;97(1):17-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Actualités dans la biologie, l'imagerie et le traitement des gliomes de l'adulte.
  • Advanced brain tumor imaging elicits a better identification of gliomas evolutive potential of.
  • In low-grade gliomas, the importance of maximal resection and the role of chemotherapy are being increasingly recognized.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / therapy. Combined Modality Therapy / methods. Diagnostic Imaging / methods. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 166
  •  go-up   go-down


60. Kaptigau WM, Ke L: Space-occupying lesions in Papua New Guinea--the CT era. P N G Med J; 2007 Mar-Jun;50(1-2):33-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 39 cases originated in the brain and its coverings and 3 in the spinal cord.
  • Out of the 39 brain SOL, 26 (67%) were due to tumours and 13 (33%) were due to infection, of which tuberculosis was responsible for 6 (46%).
  • There was also one case each of pineal tumour, craniopharyngioma, pituitary adenoma, vestibular schwannoma and oligodendroglioma and 6 indeterminate cases.
  • [MeSH-major] Brain Neoplasms / radiography. Spinal Cord Diseases / radiography
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Astrocytoma / radiography. Child. Child, Preschool. Female. Humans. Infant. Male. Meningioma / radiography. Middle Aged. Papua New Guinea. Sex Distribution. Tomography, X-Ray Computed. Young Adult


61. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Xiong NX, Zhao HY, Zhang FC, He ZQ: Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull; 2007 Jan;23(1):41-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.
  • OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown.
  • The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.
  • METHODS: Tumor tissue samples with different malignancy grade were obtained from the hospitals.
  • The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).
  • The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.
  • RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry.
  • Western-blot analysis also indicated that the gray value of Nogo-A protein band in the oligodendroglioma group was significantly higher than that in the anaplastic oligodendroglioma group.
  • CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 17592524.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
  •  go-up   go-down


63. Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW: Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer; 2009;9:450
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.
  • BACKGROUND: We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA).
  • To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas.
  • METHODS: A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in the study.
  • CONCLUSION: The present study shows that RPA grouping with clinical prognostic factors can successfully predict the survival of patients with WHO grade III glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Classification / methods. Glioma / diagnosis. Glioma / therapy. Neoplasm Staging / methods. Radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Vindesine / therapeutic use. World Health Organization

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1169-76 [18938045.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Neurology. 1994 Aug;44(8):1479-83 [8058153.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):193-6 [16611661.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):575-81 [17432706.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):307-16 [18532929.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • (PMID = 20017960.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; PCV regimen
  • [Other-IDs] NLM/ PMC2806410
  •  go-up   go-down


64. Rajesh LS, Jain D, Radotra BD, Banerjee AK, Khosla VK, Vasishta RK: Central neurocytoma: a clinico-pathological study of eight cases. Indian J Pathol Microbiol; 2006 Oct;49(4):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central neurocytoma: a clinico-pathological study of eight cases.
  • Central neurocytomas are benign neuronal tumours generally found in the lateral or third ventricles.
  • They are rare, comprising < 1% of all brain tumours.
  • It is frequently confused with other tumours of the central nervous system particularly oligodendroglioma.
  • The present series highlights the characteristic clinical and pathological findings of this rare brain tumour.
  • Immunostaining for neuronal markers are essential for distinguishing them from other small round cell tumours of the brain.
  • [MeSH-minor] Adolescent. Adult. Child, Preschool. Female. Humans. Immunohistochemistry. Intracranial Hypertension. Male. Nerve Tissue Proteins / metabolism. Synaptophysin / metabolism

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183847.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


65. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol; 2008 Sep;89(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
  • BACKGROUND: Anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) are currently treated with a combination of surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):627-42 [8120563.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):156-63 [17541945.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 18458821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


66. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC: Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol; 2005 Jun;57(6):855-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
  • To evaluate the role of molecular genetics in the routine clinic, we investigated allelic imbalance at 1p36, 19q13, 17p13, 10p12-15, and 10q22-26 and p53 mutation in 100 oligodendroglial neoplasms diagnosed at a single treatment center between 2000 and 2003.
  • Genotype was unrelated to tumor location and could not distinguish high-grade tumors that presented de novo from those that progressed from a previous lower grade malignancy.
  • In this recently diagnosed unselected series, clinical differences in tumors with and without the -1p/-19q genotype support a genetic approach to aid diagnosis and prognostication for oligodendroglial neoplasms.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 19. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Phenotype. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929038.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien); 2008 Jul;150(7):699-702; discussion 702-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic oligodendrogliomas: a review of the literature and case report.
  • Oligodendroglioma cells are detectable in the cerebro-spinal fluid in up to 14% of patients [10] and cerebellar and/or spinal cord involvement is a well known phenomenon [3].
  • Distant spread of oligodendroglioma is exceptional, probably due to the presence of the blood-brain barrier, the absence of lymphatic vessels and the short survival of patients.
  • This review was performed using NCBI-PubMed and "oligodendroglioma, oligodendrogliomas, metastatic, metastasis, metastases, extraneural", in different combinations, as key words and reviewing the bibliography of the consequent selected articles.
  • New therapeutic approaches are prolonging the overall survival of patients with primitive brain tumours and in particular of those with high grade oligodendroglioma which is a chemo-sensitive disease.
  • [MeSH-major] Brain Neoplasms / pathology. Liver Neoplasms / secondary. Occipital Lobe. Oligodendroglioma / secondary. Parietal Lobe
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Neurochir (Wien). 2009 Aug;151(8):987 [19424658.001]
  • (PMID = 18548193.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 29
  •  go-up   go-down


68. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P: Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer; 2006 Aug 15;119(4):792-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
  • Loss of heterozygosity (LOH) on chromosomal arms 1p and 19q is the most common genetic alteration in oligodendroglial tumors and associated with response to radio- and chemotherapy as well as favorable prognosis.
  • Using microsatellite analysis, we previously identified the chromosomal regions 1p36.22-p36.31 and 19q13.3, as candidate tumor suppressor gene regions being commonly deleted in these tumors.
  • To identify genes within these regions that are downregulated in oligodendroglial tumors with LOH 1p/19q, we performed cDNA microarray-based RNA expression profiling of 35 gliomas with known allelic status on 1p and 19q, including 7 oligodendrogliomas and 8 diffuse astrocytomas of World Health Organization (WHO) grade II, as well as 14 anaplastic oligodendrogliomas and 6 anaplastic oligoastrocytomas of WHO grade III.
  • In addition, we found that the cytosolic phospholipase A2 (PLA2G4C) gene at 19q13.3 demonstrated significantly lower expression in anaplastic oligodendrogliomas (WHO grade III) when compared to well-differentiated oligodendrogliomas (WHO grade II).
  • Taken together, our study provides a set of interesting novel candidate genes that may play important roles in the pathogenesis of oligodendroglial tumors.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Oligodendroglioma / genetics. Oligonucleotide Array Sequence Analysis. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA, Complementary / genetics. Down-Regulation. Female. Humans. Male. Middle Aged. Transcription, Genetic / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16550607.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


69. Wu A, Aldape K, Lang FF: High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. J Neurooncol; 2010 Aug;99(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.
  • It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.
  • In the context of this claim, we analyzed a series of insular oligodendroglial tumors in order to determine the frequency of 1p/19q co-deletion in tumors arising in this region.
  • Four (50%) of eight oligodendrogliomas and four (67%) of six oligoastrocytomas demonstrated 1p/19q co-deletions.
  • Seven of the eight tumors with co-deletion of 1p/19q were WHO grade II gliomas.
  • There were no statistical differences between tumors with 1p/19q co-deletion compared to those with 1p and/or 19q intact in terms of age, preoperative KPS, presenting symptoms, left versus right lateralization, tumor location (purely insular versus extension into frontal or temporal lobe), preoperative tumor size.
  • In contradistinction to previous reports, loss of 1p/19q occurs commonly in insular oligodendroglial tumors.
  • With respect to 1p/19q, insular gliomas do not appear to be distinct from gliomas arising elsewhere in the brain.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1891-7 [16986124.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):638-50 [11596959.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2622-6 [15197805.001]
  • [Cites] Brain Res Brain Res Rev. 1996 Oct;22(3):229-44 [8957561.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):87-93 [9525843.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 2004 Dec 28;63(12):2360-2 [15623700.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):176-83; discussion 176-83 [15987586.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E15 [16398465.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):639-52 [17440165.001]
  • [Cites] Acta Neurobiol Exp (Wars). 2007;67(2):103-12 [17691218.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):293-8 [18345516.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]
  • [Cites] J Neurooncol. 2009 Jan;91(1):1-5 [18726074.001]
  • [Cites] J Neurosurg. 2010 Jan;112(1):1-9 [19612970.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • (PMID = 20035368.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115729-04; United States / NCI NIH HHS / CA / P50CA127001; United States / NCI NIH HHS / CA / R01 CA115729; United States / NCI NIH HHS / CA / P50 CA127001; United States / NCI NIH HHS / CA / R01 CA115729-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS172388; NLM/ PMC2891585
  •  go-up   go-down


70. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


71. Tanaka Y, Sasaki A, Ishiuchi S, Nakazato Y: Diversity of glial cell components in pilocytic astrocytoma. Neuropathology; 2008 Aug;28(4):399-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In PA, Olig2 immunoreactivity was significantly expressed in protoplasmic astrocytes in microcystic, loose areas and cells in oligodendroglioma-like areas.
  • [MeSH-major] Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Nerve Tissue Proteins / biosynthesis. Neuroglia / metabolism
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. DNA-Binding Proteins / biosynthesis. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Ki-67 Antigen / biosynthesis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312545.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AIF1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


72. da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T: Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz); 2008 Jul-Aug;56(4):267-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas commonly overexpress the oncogenes EGFR and PDGFR and contain mutations and deletions of the tumor suppressor genes PTEN and TP53.
  • Intranasal delivery allows drugs that do not cross the blood-brain barrier to enter the central nervous system.
  • MATERIALS AND METHODS: Applying this method, a phase I/II clinical trial of POH was performed in patients with relapsed malignant gliomas after standard treatment: surgery, radiotherapy, and chemotherapy.
  • The cohort consisted of 37 patients, including 29 with glioblastoma multiforme (GBM), 5 with grade III astrocytoma (AA), and 3 with anaplastic oligodendroglioma (AO).
  • Complete response was defined as neurological stability or improvement of conditions, disappearance of CT/MRI tumor image, and corticosteroid withdraw; partial response (PR) as > or =50 reduction of CT/MRI tumor image, neurological stability, or improvement of conditions and corticosteroid requirement; progressive course (PC) as > or =25 increase in CT/MRI tumor image or the appearance of a new lesion; and stable disease as a lack of any changes in the CT/MR tumor image or neurological status.
  • There were no toxicity events and the regression of tumor size in some patients is suggestive of antitumor activity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Mitogen-Activated Protein Kinase Kinases / metabolism. Monoterpenes / therapeutic use. ras Proteins / metabolism
  • [MeSH-minor] Administration, Intranasal. Adult. Aged. Apoptosis / drug effects. Astrocytoma / drug therapy. Astrocytoma / metabolism. Disease-Free Survival. Female. Glioblastoma / drug therapy. Glioblastoma / metabolism. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Oligodendroglioma / drug therapy. Oligodendroglioma / metabolism. Signal Transduction / drug effects


73. Quigg M, Geldmacher DS, Elias WJ: Conduction aphasia as a function of the dominant posterior perisylvian cortex. Report of two cases. J Neurosurg; 2006 May;104(5):845-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assessment of eloquent functions during brain mapping usually relies on testing reading, speech, and comprehension to uncover transient deficits during electrical stimulation.
  • The authors report two cases that demonstrate that conduction aphasia is cortically mediated and can be inadequately assessed if not specifically evaluated during brain mapping.
  • To determine the distribution of language on the dominant cortex, electrical cortical stimulation was performed in two cases by using implanted subdural electrodes during brain mapping before epilepsy surgery.
  • Brain mapping of this region should include assessment of verbal repetition to avoid potential deficits resembling conduction aphasia.
  • [MeSH-major] Aphasia, Conduction / etiology. Brain Mapping. Brain Neoplasms / physiopathology. Cerebral Cortex / physiopathology. Dominance, Cerebral / physiology. Epilepsy, Complex Partial / physiopathology. Hemangioma, Cavernous / physiopathology. Oligodendroglioma / physiopathology. Postoperative Complications / etiology
  • [MeSH-minor] Adult. Electric Stimulation. Electrodes, Implanted. Female. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Neuropsychological Tests

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703895.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Seol HJ, Kim JE, Wang KC, Kim SK, Seo JS, Park SH, Jung HW: The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors. Int J Oncol; 2009 Jan;34(1):181-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors.
  • StAR is expressed at a very low level in the white matter of the normal human brain, but is highly expressed in several brain neoplasms including oligodendroglioma (OD).
  • The aim of this study was to identify the different patterns of gene expression low-grade OD and high-grade OD.
  • There was a difference in genetic expression between low- and high-grade ODs.
  • The expression of such genes showed a tendency either of decreasing or mildly increasing, in high-grade ODs, compared with low-grade ODs.
  • Real-time PCR showed that expression of StAR was relatively low in high-grade ODs, in comparison with low-grade ODs.
  • The pattern of expression between low- and high-grade ODs can differ.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / genetics. Gene Expression Profiling. Oligodendroglioma / genetics. Steroids / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphoproteins / genetics. Phosphoproteins / metabolism. RNA, Neoplasm. Transcription, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082489.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Phosphoproteins; 0 / RNA, Neoplasm; 0 / Steroids; 0 / steroidogenic acute regulatory protein
  •  go-up   go-down


75. Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM: Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol; 2009 May;92(3):373-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.
  • 1p19q LOH has been shown to predict radio- and chemosensitivity and prolonged survival in oligodendrogliomas (OLs).
  • We have recently shown that magnetic resonance perfusion-weighted imaging (MR-PWI) may be useful in predicting the histopathological grade or cytogenetic type of oligodendroglial neoplasms.
  • MR-PWI allows noninvasive determination of relative tumor blood volume (rTBV), which may reflect the degree of neoplastic angiogenesis and metabolism.
  • The present study was aimed to correlate rTBV to the angiogenic markers and EGFR expression in oligodendroglial tumors with 1p/19q LOH or 1p LOH (Group 1) and 1p19q intact alleles or 19q LOH (Group 2), respectively.
  • In WHO grade II neoplasms, Group 1 showed significantly greater rTBV than Group 2 (P = 0.013).
  • However, the differences between Group 1 and Group 2 were not significant in grade III tumors.
  • Probe-based real-time RT-PCR analyses showed that 12% of Group 2 high-grade tumors with intact 1p19q exhibited dramatic EGFR overexpression (designated EGFR-high).
  • Grade III neoplasms showed a significantly higher rTBV than grade II neoplasms.
  • Therefore, the combined use of extensive molecular profiling and advanced MR imaging modalities may improve the accuracy of tumor grading, provide prognostic information, and has the potential to influence treatment decisions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / diagnosis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Magnetic Resonance Angiography. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1998;16(4):225-30 [9589031.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] FASEB J. 2003 Jun;17 (9):984-92 [12773481.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):268-75 [11987155.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):17-23 [18181830.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):600-9 [17886561.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):540-7 [18544654.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] J Intern Med. 2004 May;255(5):538-61 [15078497.001]
  • [Cites] Eur J Radiol. 2003 Dec;48(3):244-51 [14652141.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] Stat Med. 1995 Apr 30;14(8):811-9 [7644861.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):475-82 [16161080.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):139-46 [10656442.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1671-80 [11092527.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):738-45 [11857307.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):777-83 [15814920.001]
  • [Cites] Mol Cancer. 2008 May 20;7:41 [18492260.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):109-20 [11245271.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Oct;28(9):1683-9 [17893221.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):114-9 [10713942.001]
  • [Cites] Neurosurgery. 2005 May;56(5):919-26; discussion 919-26 [15854239.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1995;222:43-60 [7569746.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 19357963.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-90586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


76. Opris I, Ducrotoy V, Bossut J, Lamy A, Sabourin JC: Oligodendroglioma arising in an ovarian mature cystic teratoma. Int J Gynecol Pathol; 2009 Jul;28(4):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma arising in an ovarian mature cystic teratoma.
  • SUMMARY: We describe a case of oligodendroglioma arising in an ovarian mature cystic teratoma associated with a loss of heterozygosity on the long arm of chromosomes 19 and 10.
  • These findings were consistent with a low-grade oligodendroglioma arising in a mature ovarian cystic teratoma.
  • Reverse transcription-polymerase chain reaction analysis showed a characterized loss of heterozygosity occurring in tumor DNA on chromosomes 10q and 19q13.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Oligodendroglioma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483626.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Durmaz R, Vural M, Işildi E, Coşan E, Ozkara E, Bal C, Ciftçi E, Arslantaş A, Atasoy MA: Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg; 2008 Oct;18(4):336-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of prognostic factors on survival in patients with low grade glioma.
  • AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.
  • The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).
  • The medical records of the patients were reviewed for age, gender, tumor locations, extent of resection, and presence of seizure, the neurological status as defined by the Karnofsky Performance Scale (KPS) and radiotherapy treatment after surgery as possible prognostic factors.
  • Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.
  • Young age, histology subtype (oligodendroglioma) and preoperative KPS were determined to have positive influence on survival according to Log Rank Test.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Glioma / mortality. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult


78. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R: Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol; 2009 Dec;22(12):1600-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
  • It is unclear how annexin-1 is expressed in various neuroepithelial tumors, and whether there is any association with tumor malignancy or survival.
  • We studied annexin-1 expression in 394 glial neoplasms of all grades of malignancy and 81 normal brain samples by immunohistochemistry using tissue microarrays.
  • In the normal human brain, the expression of annexin-1 is limited to ependymal cells and subependymal astrocytes, but is also upregulated in reactive astrocytes.
  • Ependymomas and astrocytomas showed significantly higher mean annexin-1 expression levels in the cytoplasm compared with oligodendrogliomas (both: P<0.0001).
  • In addition, nuclear staining of annexin-1 in oligodendroglial tumor cells was significantly reduced (P=0.0002), which may be used as a diagnostic tool for differentiating between astrocytomas and oligodendrogliomas.
  • Although annexin-1 expression in ependymomas decreased with the grade of malignancy, diffuse astrocytomas showed a significant increase in cytoplasmic annexin-1-positive tumor cells.
  • Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof.
  • [MeSH-major] Annexin A1 / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Glioma / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / chemistry. Blotting, Western. Cell Nucleus / chemistry. Child. Child, Preschool. Ependymoma / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / chemistry. Prognosis. Receptor, Epidermal Growth Factor / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Time Factors. Tissue Array Analysis. Young Adult


79. Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res; 2008 Mar 10;1198:16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
  • This SNP has never been specifically investigated in a large series of oligodendroglial tumors.
  • In a comparison with 232 healthy controls, we retrospectively analyzed blood samples of 293 oligodendroglial tumor patients for MDM2 SNP309.
  • In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial tumors, were investigated.
  • The frequencies of T/T, T/G, and G/G genotypes in patients and controls did not suggest an increased risk of oligodendroglial tumor formation correlating with MDM2 SNP309.
  • A borderline association was found between MDM2 SNP309 and overall survival (p=0.05), but in multivariate analysis, MDM2 SNP309 did not provide prognostic information complementary to age, tumor phenotype, grade, and 1p/19q status in oligodendroglial tumors.
  • Finally, MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Oligodendroglioma / genetics. Polymorphism, Single Nucleotide / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chromosomes, Human, Pair 1 / genetics. DNA Mutational Analysis. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Phenotype. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262501.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


80. Tena-Suck ML, Moreno-Jiménez S, Alonso M, Aguirre-Crux L, Sánchez A: Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. Ann Diagn Pathol; 2008 Oct;12(5):313-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.
  • Oligodendroglioma usually arise in adults and rarely in children.
  • The objective of the current study was to evaluate the immunoexpression of glial fibrillary acidic protein (GFAP) and heat shock proteins (HSP70), endothelial vascular growth factor (EVGF), and endothilial vascular growth factor receptor type II (EFGF-R) expression in relation to the proliferation labeling index (proliferating cell nuclear antigen [PCNA]) and vascular density in patients with oligodendroglioma.
  • We studied 28 cases of oligodendrogliomas--20 (71.4%) were oliodendrogliomas (grade II), and 8 (28.6%) cases were anaplastic oligodendroglioma (grade II according to World Health Organization classification).
  • Mitosis were found in grade II (0.35 +/- 1.14) and grade III (3.88 +/- 1.81) (P = .0001*) and pleomorphism in grade II (4.40 +/- 0.99) and grade III (9.50 +/- 9.20) (P = .028).
  • The GFAP was positive in grade II (1.45 +/- 0.60) and grade III (2.63 +/- 0.52) (P = .000); HSP70 was immunoreactive in grade II (1.35 +/- 0.59) and grade III (2.50 +/- 0.53) (P = .001); and EVGF was immunoreactive in grade II (22.70 +/- 6.10) and grade III (36 +/- 1.63) (P = .043).
  • The EVGF-RII was immunoreactive in grade II, 18.30 +/- 6.11 and 31.63 +/- 4.93 (P = .045).
  • The microvascular density labeling index rates were 20.70 +/- 4.34 (grade II) and 33.38 +/- 5.29 (P = .000), and the PCNA labeling index rates were 32.95 +/- 5.89 (grade II) and 56.88 +/- 5.62 (grade III) (P = .045).
  • We observed astrocyte differentiation in oligodendrogliomas grade III.
  • We found a higher PGAF, HSP70, EVGF, and EFGF-R expression in relation with the PCNA and vascular density (CD34) in patients with oligodendroglioma grade III than in oligodendroglioma grade II.
  • There was a significant relationship between mitosis, glial fibrillary acidic protein (GFAP), HSP70, EVGF, EVGF-receptor II expression, and the histologic grade and size of the tumor.
  • For that reason, we suggest that the correlation between GFAP and HSP70 could have a relationship with the protection mechanism of the tumor itself.
  • [MeSH-major] Astrocytes / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Cell Proliferation. Cell Transformation, Neoplastic. Female. Fluorescent Antibody Technique, Direct. Glial Fibrillary Acidic Protein / analysis. HSP70 Heat-Shock Proteins / analysis. Humans. Male. Middle Aged. Mitosis. Proliferating Cell Nuclear Antigen / metabolism. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-2 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774492.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / HSP70 Heat-Shock Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


81. Klysik M, Gavito J, Boman D, Miranda RN, Hanbali F, De Las Casas LE: Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker. Diagn Cytopathol; 2010 Mar;38(3):202-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker.
  • Intraoperative cytologic evaluation of brain tumors has been used either to render a preliminary interpretation or more often as a complement to frozen section examination.
  • Central neurocytoma is a intraventricular neoplasm, typically located in the region of the foramen of Monro, affecting mostly young to middle age adults.
  • Histologically, central neurocytomas are characterized by monotonous cells with round nuclei and neuronal differentiation within a rich capillary network.
  • Their distinction during intraoperative consultations from oligodendroglioma, ependymoma (mainly clear cell ependymoma), and non-Hodgkin lymphoma can be a diagnostic challenge.
  • We report a case of a 19-year-old female with an intraventricular tumor where imprint cytology preparations were crucial for the intraoperative diagnosis of central neurocytoma.
  • Imprint cytology preparations show a round cell neoplasm associated with neuropil clumps and short straight capillaries admixed with tumor cell clusters.
  • To the best of our knowledge, only a few cases describing the cytologic findings of central neurocytomas have been reported in the medical literature.
  • [MeSH-major] Brain Neoplasms / pathology. Cytodiagnosis / methods. Neurocytoma / pathology. Oligodendroglioma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Ependymoma / diagnosis. Female. Humans. Immunoenzyme Techniques. Intraoperative Period. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome. Young Adult


82. Glanz C, Rebetz J, Stewénius Y, Persson A, Englund E, Mandahl N, Mertens F, Salford LG, Widegren B, Fan X, Gisselsson D: Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability. Neuropathol Appl Neurobiol; 2007 Aug;33(4):440-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability.
  • Glioblastoma multiforme (GBM) and other high-grade brain tumours are typically characterized by complex chromosome abnormalities and extensive intratumour cytogenetic heterogeneity.
  • In this study, we analysed the pattern of chromosome segregation at mitosis in 20 brain tumours.
  • Anaphase bridging was also found in two medulloblastomas (7-15%), one anaplastic astrocytoma (17%) and one oligodendroglioma (6%).
  • In contrast, cell division abnormalities were not found in low-grade brain tumours with less complex karyotypes, including two pilocytic astrocytomas and two ependymomas.
  • Telomere-dependent abnormal segregation of chromosomes at mitosis is thus a common phenomenon in high-grade brain tumours and may be one important factor behind cytogenetic intratumour diversity in GBM.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Spindle Apparatus / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Animals. Cells, Cultured. Child. Child, Preschool. Chromatids / genetics. Chromosome Segregation / physiology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged. Neoplasm Transplantation. Phenotype. Sister Chromatid Exchange / genetics. Telomerase / antagonists & inhibitors. Telomerase / metabolism. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617873.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


83. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA: Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery; 2010 Jan;66(1):48-58; discussion 58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
  • OBJECTIVE: Refractory anaplastic oligodendroglioma and oligoastrocytoma tumors are challenging to treat.
  • This trial primarily evaluated toxicity and estimated the maximum tolerated dose of intra-arterial (IA) melphalan, IA carboplatin, and intravenous (IV) etoposide phosphate in conjunction with blood-brain barrier disruption in these tumors.
  • METHODS: Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year.
  • Patients underwent melphalan dose escalation (4, 8, 12, 16, and 20 mg/m(2)/d) until the maximum tolerated dose (1 level below that producing grade 4 toxicity) was determined.
  • RESULTS: Two of 4 patients receiving IA melphalan at 8 mg/m(2)/d developed grade 4 thrombocytopenia; thus, the melphalan maximum tolerated dose was 4 mg/m/d.
  • Adverse events included asymptomatic subintimal tear (1 patient) and grade 4 thrombocytopenia (3 patients).
  • CONCLUSION: In patients with anaplastic oligodendroglioma or oligoastrocytoma tumors in whom temozolomide treatment has failed, osmotic blood-brain barrier disruption with IA carboplatin, IV etoposide phosphate, and IA melphalan (4 mg/m(2)/d for 2 days) shows acceptable toxicity and encouraging efficacy, especially in patients demonstrating 1p and/or 19q deletion.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1980 Jul;7(1):36-43 [6774280.001]
  • [Cites] J Pharmacol Exp Ther. 1981 Nov;219(2):281-6 [7288620.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):86-94 [7037033.001]
  • [Cites] J Biol Chem. 1982 Nov 25;257(22):13704-12 [6128339.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1984 Sep 15;54(6 Suppl):1160-7 [6467147.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):876-80 [2997415.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):831-42 [3908898.001]
  • [Cites] Biochem Pharmacol. 1987 Jan 1;36(1):147-53 [3801051.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):917-9 [2836567.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):371-8 [2536804.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):904-11 [2738624.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] Anticancer Res. 1991 Nov-Dec;11(6):2231-7 [1776864.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1220-3 [1310889.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):452-8 [1311026.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):512-6; discussion 516-7 [1316564.001]
  • [Cites] Surg Neurol. 1994 Jan;41(1):19-27 [8310382.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1994 Sep;35(3):378-88; discussion 388 [7800129.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):436-49 [7856753.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1786-99 [7602368.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2099-106 [7554060.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8 [8587686.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):251-8 [8847559.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):125-33; discussion 133-4 [8805148.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1129-36 [9067283.001]
  • [Cites] J Neurosurg. 1997 Apr;86(4):603-9 [9120622.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):121-31 [9266448.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):871-82 [9499449.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):131-40; discussion 141-2 [14683550.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] Hear Res. 2004 Jul;193(1-2):25-30 [15219317.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):84-96 [18093565.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):533-40 [18223229.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E11 [17134113.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1145-51 [17284616.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):581-8 [18072268.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):235-41 [17909806.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):187-93 [18458821.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):231-8 [18480965.001]
  • [Cites] Surg Oncol Clin N Am. 2008 Oct;17(4):919-33, xi [18722926.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3503-9 [19451444.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):797-805 [11181909.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):309-15 [10656463.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):704-9 [10719867.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):599-605 [10761648.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):493-500 [11297239.001]
  • [Cites] Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1 [11334269.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3333-9 [11454880.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):216-24 [11937000.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1807-10 [12427643.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2305-11 [12805331.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1727-31 [14630676.001]
  • [Cites] Surgery. 2004 Aug;136(2):210-8 [15300182.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):519-26 [884689.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100 [9588554.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1549-55 [9626476.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):537-42 [9683790.001]
  • [Cites] Neurosurgery. 1998 Oct;43(4):879-86; discussion 886-9 [9766316.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Anesth Analg. 1999 Mar;88(3):559-67 [10072006.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):258-65 [15709122.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):222-5 [15770640.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Sep;314(3):1052-8 [15951398.001]
  • [Cites] J Neurooncol. 2006 May;77(3):279-84 [16314949.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer J Sci Am. 1996 May-Jun;2(3):166-74 [9166517.001]
  • (PMID = 20023537.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053468; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / R01 NS053468-03; United States / NINDS NIH HHS / NS / NS044687-26; United States / NINDS NIH HHS / NS / R01 NS034608; United States / NCI NIH HHS / CA / CA137488; United States / NINDS NIH HHS / NS / R37 NS044687-26; United States / NINDS NIH HHS / NS / R37 NS044687; United States / NINDS NIH HHS / NS / NS053468-03; United States / NINDS NIH HHS / NS / NS44687; United States / NCI NIH HHS / CA / R01 CA137488-15; United States / NCI NIH HHS / CA / CA137488-15; United States / NINDS NIH HHS / NS / R01 NS044687; United States / NCI NIH HHS / CA / R01 CA137488
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS161269; NLM/ PMC2806091
  •  go-up   go-down


84. Quon H, Abdulkarim B: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev; 2008;(2):CD007104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
  • Outcomes analyzed include overall survival (OS), progression-free survival (PFS), and treatment toxicity greater than or equal to grade 3.
  • SEARCH STRATEGY: Cochrane Central Register for Controlled Trials (CENTRAL, Issue 4,2006), MEDLINE (1966 to 2006) and EMBASE (1988 to 2006) were searched.
  • Tumors with 1p and 19q co-deletions are associated with better OS and may indicate a more chemo-responsive tumor.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;5:CD007104 [24833028.001]
  • (PMID = 18425979.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 11
  •  go-up   go-down


85. Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR: Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol; 2009 Jun;117(6):657-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma (PA) is the most common pediatric brain tumor.
  • We identified four pathological features (necrosis, oligodendroglioma-like features, vascular hyalinization, and calcification) that showed a significant correlation with decreased event-free survival (EFS).
  • Lastly, we did find a statistical trend between EFS and the number of CD68+ cells, suggesting that non-neoplastic elements of the tumor microenvironment may influence subsequent growth and clinical recurrence.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain / pathology. Brain / physiopathology. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Male. Mitotic Index. Retrospective Studies. Signal Transduction. Tumor Suppressor Protein p53 / metabolism. Young Adult


86. Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ: Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res; 2009 Oct 15;15(20):6430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
  • PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis.
  • EXPERIMENTAL DESIGN: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done.
  • In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and overall survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively).
  • Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048).
  • CONCLUSION: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):305-9 [10606174.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):77-86 [18617055.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):16-25 [10918389.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4760-3 [8062276.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1809-13 [8625052.001]
  • [Cites] Cancer. 1996 Sep 1;78(5):1107-13 [8780550.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):802-9 [15637687.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1468-77 [16088966.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5010-6 [17311001.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • (PMID = 19808867.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057683-16; United States / NCI NIH HHS / CA / R01 CA057683; United States / NCI NIH HHS / CA / R01 CA057683-16
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS160000; NLM/ PMC2818514
  •  go-up   go-down


87. Yang LS, Huang FP, Zheng K, Zhang HS, Zhou X, Bao XH, Zheng JJ, Chang C, Zhou LF: Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients. J Neurooncol; 2010 Oct;100(1):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.
  • Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Drug Therapy. Female. Humans. Karnofsky Performance Status. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male. Middle Aged. Prognosis. Radiotherapy. Retrospective Studies. Tomography Scanners, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Oncology. 2003;65(3):259-66 [14657600.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):959-66; discussion 966 [8084406.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] Chin Med J (Engl). 2008 Jun 20;121(12):1072-5 [18706219.001]
  • [Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1345-52 [3545437.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):159-68 [16821091.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):189-93 [16132506.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • (PMID = 20195700.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


88. Puget S, Rutka JT: Malignant brain tumors: two steps forward. Clin Neurosurg; 2007;54:4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant brain tumors: two steps forward.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Neurosurgical Procedures / trends
  • [MeSH-minor] Adult. Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / surgery. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Disease Progression. Female. Forecasting. Gene Expression Profiling. Humans. Male. Medulloblastoma / drug therapy. Medulloblastoma / genetics. Medulloblastoma / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics. Oligodendroglioma / surgery. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18504889.001).
  • [ISSN] 0069-4827
  • [Journal-full-title] Clinical neurosurgery
  • [ISO-abbreviation] Clin Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Ertan Y, Sarsik B, Ozgiray E, Kitis O, Dalbasti T, Akalin T: Pigmented ependymoma with signet-ring cells and Rosenthal fibers: a rare variant of ependymoma. Neuropathology; 2010 Feb 1;30(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was composed of cells with cytoplasmic vacuoles, signet cells and clear cells.
  • The clear cells were compactly arranged resembling oligodendroglioma.
  • Additionally, some tumor cells contained brown cytoplasmic pigment, which was histochemically compatible with lipofuscin and neuromelanin.
  • On immunohistochemical examination, the tumor cells were positive for S100, glial fibrillary acidic protein and vimentin, and negative for synaptophysin, cytokeratin, neurofilament and HMB45.
  • [MeSH-major] Brain / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Fourth Ventricle / pathology. Pigmentation
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508348.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


90. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


91. Ishiwata K, Tsukada H, Kubota K, Nariai T, Harada N, Kawamura K, Kimura Y, Oda K, Iwata R, Ishii K: Preclinical and clinical evaluation of O-[11C]methyl-L-tyrosine for tumor imaging by positron emission tomography. Nucl Med Biol; 2005 Apr;32(3):253-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical and clinical evaluation of O-[11C]methyl-L-tyrosine for tumor imaging by positron emission tomography.
  • The whole-body imaging of monkeys and healthy humans by PET showed low uptake of O-[11C]methyl-L-tyrosine in all normal organs except for the urinary track and bladder, suggesting that the O-[11C]methyl-L-tyrosine PET has the potential for tumor imaging in the whole-body.
  • Finally, the brain tumor imaging was preliminarily demonstrated.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Oligodendroglioma / metabolism. Oligodendroglioma / radionuclide imaging. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Animals. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / radionuclide imaging. Cell Line, Tumor. Drug Evaluation, Preclinical. Female. Haplorhini. Humans. Inflammation / metabolism. Inflammation / radionuclide imaging. Male. Metabolic Clearance Rate. Organ Specificity. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / chemical synthesis. Rats. Survival Analysis. Tissue Distribution. Turpentine

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. TURPENTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820760.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(11C)methyl-L-tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine; 8006-64-2 / Turpentine
  •  go-up   go-down


92. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther; 2006 Apr;5(4):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
  • The poor prognosis of patients with high-grade glioma has led to the search for new therapeutic strategies.
  • In order to evaluate safety, immunogenicity and preliminary efficacy of h-R3 in newly diagnosed high-grade glioma patients, we conducted a Phase I/II trial.
  • Tumor types were: glioblastoma (GB) (16 patients), anaplastic astrocytoma (AA) (12 patients) and anaplastic oligodendroglioma (AO) (1 patient).
  • No evidences of grade 3/4 adverse events were detected.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Astrocytoma / therapy. Glioblastoma / therapy. Glioma / pathology. Glioma / therapy. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Adult. Aged. Antibodies / chemistry. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Organotechnetium Compounds. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575203.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-hR3 monoclonal antibody; 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organotechnetium Compounds; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


93. Preusser M, Haberler C, Hainfellner JA: Malignant glioma: neuropathology and neurobiology. Wien Med Wochenschr; 2006 Jun;156(11-12):332-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas comprise a spectrum of different tumor subtypes.
  • Within this spectrum, glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma share as basic features preferential location in cerebral hemispheres, diffuse infiltration of brain tissue, fast tumor growth with fatal outcome within months or years.
  • Invasion of glioma cells requires interaction with the extracellular matrix and with surrounding cells of the healthy brain tissue.
  • These features are most likely the consequence of rapidly increasing tumor mass that is inadequately oxygenized by the preexisting vasculature.
  • Methylguanine-methyltransferase (MGMT) promoter methylation status in glioblastoma and 1p19q deletion status in anaplastic oligodendroglioma are associated with response to chemotherapy.
  • The role of neuropathology and neurobiology in neurooncology is 1. to provide a clinically meaningful classification of brain tumors on basis of pathobiological factors, 2. to clarify etiology and pathogenesis of brain tumors as rational basis for development of new diagnostic tests and therapies, and 3. to translate testing for new clinically relevant molecular parameters into clinical application.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Adult. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Chromosome Aberrations. Female. Humans. Infant. Male. Neoplasm Invasiveness / pathology. Prognosis


94. Hlaihel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F: Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol; 2010 Mar;97(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas.
  • The aim of our study was to evaluate the role of proton magnetic resonance (MR) spectroscopy and MR perfusion in the follow-up of low-grade gliomas, since conventional MR imaging (MRI) is not reliable in detecting the passage from a low- to high-grade tumor.
  • Twenty-one patients with a World Health Organisation (WHO) grade II glioma were followed up using proton MR spectroscopy, perfusion, and conventional MRIs.
  • The mean annual growth of low-grade glioma was 3.65 mm.
  • Proton magnetic resonance spectroscopy should be recommended in the follow-up of low-grade gliomas since the choline/creatine ratio can predict anaplastic transformation before perfusion abnormalities, with high positive predictive value of 83%.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Cerebrovascular Circulation / physiology. Choline / metabolism. Contrast Media. Creatine / metabolism. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Protons. ROC Curve. Regional Blood Flow

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2007 Jan;188(1):204-12 [17179366.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):784-90 [15814921.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Nov;29(10):1872-7 [18719036.001]
  • [Cites] Radiology. 2008 Apr;247(1):170-8 [18372467.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):660-6 [17432719.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):12-26 [16443944.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):458-63 [18065512.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Radiologe. 2007 Sep;47(9):812-8 [16924439.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):74-81 [12546355.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] J Neurooncol. 2009 May;92(3):317-35 [19357959.001]
  • [Cites] Life Sci. 1996;58(22):1929-35 [8637421.001]
  • [Cites] Neuroradiology. 2005 Dec;47(12):887-91 [16133483.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):47-52 [1650241.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):947-9 [12297589.001]
  • [Cites] Ann Neurol. 2003 Apr;53(4):524-8 [12666121.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):233-45 [12892229.001]
  • [Cites] J Neurosci. 1993 Mar;13(3):981-9 [8441018.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Ann Neurol. 2006 Sep;60(3):380-3 [16983683.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):823-9 [11564242.001]
  • [Cites] Neurol Res. 2009 Nov;31(9):931-9 [19215664.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):688-93 [18184842.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] Eur Neurol. 2007;58(4):198-209 [17823533.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]
  • (PMID = 19727562.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


95. Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B, Husband DJ, Warnke PC, Walker C: Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology; 2006 Oct;48(10):703-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
  • INTRODUCTION: The biological factors responsible for differential chemoresponsiveness in oligodendroglial tumours with or without the -1p/-19q genotype are unknown, but tumour vascularity may contribute.
  • We aimed to determi